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PCoronary Stents
Looking Forward
Scot Garg, MB, CHB, Patrick W. Serruys, MD, PHD
Rotterdam, the Netherlands
Despite all the benefits of drug-eluting stents (DES), concerns have been raised over their long-term safety, with
particular reference to stent thrombosis. In an effort to address these concerns, newer stents have been devel-
oped that include: DES with biodegradable polymers, DES that are polymer free, stents with novel coatings, and
completely biodegradable stents. Many of these stents are currently undergoing pre-clinical and clinical trials;
however, early results seem promising. This paper reviews the current status of this new technology, together
with other new coronary devices such as bifurcation stents and drug-eluting balloons, as efforts continue to
design the ideal coronary stent. (J Am Coll Cardiol 2010;56:S43–78) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.008r
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part 1 has highlighted the impressive clinical benefits seen
ollowing the introduction of drug-eluting stents (DES);
owever, in parallel, it also serves to highlight the safety
oncerns associated with their use, which have predomi-
antly centered around stent thrombosis (ST) (1–3). The
ause of ST is clearly multifactorial, and in addition to
atient and lesion factors, a portion of blame has been
ttributed to the stent polymer (4), which has subsequently
ecome a focal area for new research and stent development.
The second-generation DES have more biocompatible
olymers, and although they have already demonstrated
mpressive safety results at medium-term follow-up (5–7),
dditional improvements are anticipated from the newer
etallic durable polymer DES that have been developed.
espite this, however, concerns persist over the presence of
nonerodable polymer, which remains exposed to the
oronary artery environment long after its useful function
as been served. These concerns appear justified in light of
vidence from animal and human studies, which suggest
hat these nonerodable polymers can cause persistent arterial
all inflammation and delayed vascular healing, both of
hich may subsequently have a role in precipitating ST and
elayed restenosis (8–11).
The findings from these studies accelerated the develop-
ent of DES coated with biodegradable polymers. These
tents offer the attractive combination of controlled drug
lution in parallel with biodegradation of the polymer into
nert monomers. Therefore, after biodegradation is com-
lete, only a bare-metal stent (BMS) remains, thereby
rom the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical
enter, Rotterdam, the Netherlands. Drs. Garg and Serruys report that they have no
elationships to disclose.a
Manuscript received December 9, 2009; revised manuscript received June 1, 2010,
ccepted June 15, 2010.educing the long-term risks associated with the presence of
permanent polymer (12).
In recent times, an extension of this concept has been the
evelopment of DES that are completely free of polymer,
nd of BMS coated in novel coatings. Finally, completely
iodegradable magnesium and polymeric stents have been
eveloped, which completely disappear once vascular heal-
ng has taken place.
In Part 2, this new stent technology, together with other
oronary devices such as bifurcation stents and drug-eluting
alloons that are all currently undergoing investigation in
re-clinical and clinical trials, is reviewed. This new stent
echnology encompasses a wide range of devices, and
lthough not a definitive classification, devices in the fol-
owing discussion have been grouped together along similar
ypes of polymer. It must be acknowledged, however, that
his classification does not cater for all possibilities.
etallic DES With Durable Polymers
umerous new durable polymer metallic DES are under
evelopment. These stents build on the knowledge and
xperiences gained from the first- and second-generation
ES described in Part 1, while utilizing new polymer
echnology, antiproliferative agents, and metal stent plat-
orms in a bid to improve clinical outcomes and safety
Table 1) (13–17).
ew polymer technology: Endeavor Resolute. The En-
eavor Resolute zotarolimus-eluting stent (ZES) (Medtronic,
anta Rosa, California) is the next version of the Endeavor
ES and is currently undergoing clinical evaluation. This ZES
onsists of the Driver cobalt chromium stent platform and a
iolinx polymer—a blend of 3 different polymers: the hydro-
hobic C10 polymer to control drug release; the biocompatible
nd hydrophilic C19 polymer; and polyvinyl pyrrolidone to
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Coronary Stents: Looking Forward August 31, 2010:S43–78allow an early burst of drug release
(18). The polymer allows delayed
drug release, such that at least 85%
of the zotarolimus is released
within 60 days, with the remainder
being released within 180 days
(Fig. 1) (18,19). Ultimately, this
delayed release is intended to
match the delayed healing times
seen in complex lesions. Evalua-
tion of the stent in the 139-patient
multicenter, nonrandomized, first-
in-man (FIM) RESOLUTE
(Evaluation of the new generation
zotarolimus-eluting coronary stent
system) study demonstrated an
angiographic in-stent late loss of
0.22 mm at 9-months follow-up
and respective rates of major
adverse cardiovascular events
(MACE), target lesion revascu-
larization (TLR), and any defi-
nite/probable ST of 8.6%, 0.7%,
and 0.0% at 12-month follow-
up, and 11.6%, 1.6%, and 0.0%
at 3-year follow-up (13,20,21).
Further evaluation of the Reso-
lute stent has taken place in the
RESOLUTE All-Comers trial,
which enrolled 2,300 patients who
were randomized in a 1:1 ratio to
treatment with either the Resolute
ZES or the Xience V (Abbott
Vascular, Santa Clara, California)
everolimus-eluting stent (EES).
At 12-months clinical follow-up
in a predominantly off-label popu-
lation, the Resolute ZES was
found to be noninferior to EES
with respect to the primary clinical
end point of target lesion failure,
a composite of cardiac death, tar-
get vessel myocardial infarction
(MI), and clinically indicated
TLR (ZES 8.2% vs. EES 8.3%,
pnoninferiority 0.001). In addition,
in a subgroup of patients who were
randomized to 13-month angio-
graphic follow-up, ZES was again
found to be noninferior toEESwith
respect to the powered angiographic
secondary end point of in-stent di-
ameter stenosis (ZES 21.65 
14.42% vs. EES 19.76  14.64%,
p,noninferiority  0.04). Considering
Abbreviations
and Acronyms
BDS  biodegradable stent
BE  balloon-expandable
BMS  bare-metal stent(s)
BVS  bioresorbable
vascular scaffold
C.E.  Conformité
Européene
DAPT  dual antiplatelet
therapy
DEB  drug-eluting balloon
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
EPC  endothelial
progenitor cell
FDA  Food and Drug
Administration
FIM  first in man
ISR  in-stent restenosis
IVUS  intravascular
ultrasound
IVUS-VH  intravascular
ultrasound-virtual
histology
MACE  major adverse
cardiovascular events
MI  myocardial infarction
NES  novolimus-eluting
stent(s)
OCT  optical coherence
tomography
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
PF  polymer-free
PLA  poly-L-lactide
PLGA  50:50 poly
DL-lactide-co-glycolide
PLLA  poly-L-lactic acid
SES  sirolimus-eluting
stent(s)
SE  self-expanding
ST  stent thrombosis
TLR  target lesion
revascularization
TVR  target vessel
revascularization
ZES  zotarolimus-eluting
stent(s)the complex patient population, the Ne T E
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August 31, 2010:S43–78 Coronary Stents: Looking Forwardverall rate of ST was low at 2.3% and 1.5% for ZES and EES,
espectively (p  0.17) (22).
ew antiproliferative agents: Elixir DESyne novolimus-
luting stent (NES). The Elixir DESyne NES (Elixir
edical, Sunnyvale, California) consists of: 1) a cobalt
hromium stent platform (Figs. 2A and 2B); 2) a durable
oly(n-butyl methacrylate) polymer, which is similar to that
ound on the Cypher sirolimus-eluting stent (SES) (Cordis,
arren, New Jersey); and 3) a drug coating of novolimus,
hich represents a new antiproliferative mammalian target
f rapamycin (mTOR) inhibitor, which is a metabolite of
irolimus, that has been specifically developed for the stent.
his modified mTOR inhibitor has a similar efficacy to
urrently available agents; however, it has both a lower drug
ose (NES 5 g/mm of stent length vs. ZES 10 g/mm)
nd polymer load (polymer thickness 3 m vs. 4.1 m on
ES) compared with other first- and second-generation
ES, and therefore is conceivably safer.
The feasibility of using novolimus on a DES has been
ssessed in the 15-patient FIM EXCELLA (Elixir Medical
linical Evaluation of the Novolimus-Eluting Coronary
Figure 1 The Endeavor Resolute Stent
(A) The chemical structure of the 3 components of the BioLinx polymer system. Th
adequate hydrophobicity for zotarolimus. The hydrophilic C19 polymer is manufact
none and vinyl acetate monomers, to provide enhanced biocompatibility. The hydro
ibility. (B) The drug release pattern of zotarolimus; 85% is released within the fir
arterial concentrations of zotarolimus in the porcine coronary artery model at vario
Endeavor stent maintains effective drug levels through the initial loading of arteria
Resolute stent sustains an effective drug level in the tissue through continued, su
Udipi et al. (19), respectively.tent System) study, which reported an angiographic Nn-stent late loss of 0.31  0.25 mm, and a percentage
olume obstruction on intravascular ultrasound (IVUS)
f 6.0  4.4% at 8-month follow-up, together with no
ACE through 12 months (14) and 1 MACE event at
4 months (15).
Further assessment of the NES has been performed in the
ingle-blind, prospective EXCELLA-II study, which random-
zed 210 patients to treatment with either NES (n  139)
r ZES (n  71) (23). At 9-month follow-up, the primary
nd point of angiographic in-stent late loss was measured at
.11  0.32 mm and 0.63  0.42 mm in patients treated
ith NES and ZES, respectively (pnoninferiority 0.0001,
superiority 0.0001). During clinical follow-up, there were
o significant differences between stent groups in the
evice-orientated composite end point (NES 2.9% vs. ZES
.6%, p  0.45) or its individual components of cardiac
eath, target vessel MI, and clinically indicated TLR. The
ate of ST was comparable between both groups (23).
ew metal stent platforms: platinum chromium Element
tent platform. A platinum chromium alloy forms the basis
f the new Element stent platform (Boston Scientific,
rophobic C10 polymer is based on hydrophobic butyl methacrylate to provide
om a mixture of hydrophobic hexyl methacrylate, and hydrophilic vinyl pyrrolidi-
polyvinyl pyrrolidinone increases the initial drug burst and enhances biocompat-
days, with drug elution complete by 180 days. (C) A comparison of the relative
es post-implantation of the Endeavor and Endeavor Resolute stents. The
e with zotarolimus during the first 2 weeks of elution. Conversely, the Endeavor
d elution. B and C are reproduced with permission from Meredith et al. (18) ande hyd
ured fr
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Coronary Stents: Looking Forward August 31, 2010:S43–78verolimus on the Promus Element (Boston Scientific)
ES, and gained the Conformité Européene (C.E.) mark in
ovember 2009 (Figs. 2C and 2D). The Element platform
s also available combined with paclitaxel on the TAXUS
lement (Boston Scientific) paclitaxel-eluting stent (PES),
hich received C.E. mark in May 2010. Platinum chro-
ium offers distinct advantages over stainless steel and
obalt chromium; the alloy is twice as dense as iron or cobalt
hromium, and therefore has much greater radio-opacity. In
ddition, its increased radial strength enables thinner stent
truts, which has been shown to reduce clinical and angio-
raphic restenosis (24,25).
The Promus Element, which has a strut thickness of 81
m compared with 96 m for the TAXUS Liberté, has
een compared with the cobalt chromium Promus EES
Boston Scientific) in 1,532 patients in the randomized
ulticenter PLATINUM (A Prospective, Randomized,
ulticenter Trial to Assess an Everolimus-Eluting Coro-
ary Stent System [PROMUS Element] for the Treatment
f up to Two De Novo Coronary Artery Lesions) clinical
rial. Two parallel subtrials will also evaluate the Promus
lement stent in small vessels and in long lesions. The trial
ompleted enrolment in September 2009, and results will be
sed to support U.S. Food and Drug Administration (FDA)
pproval.
The TAXUS Element stent is currently undergoing
valuation in the ongoing PERSEUS (A Prospective Eval-
ation in a Randomized Trial of the Safety and Efficacy of
he Use of the TAXUS Element Paclitaxel-Eluting Coro-
ary Stent System for the Treatment of De Novo Coronary
rtery Lesions) clinical trial program, which has so far
eported results from 2 parallel studies in patients with
C
A
Figure 2 Examples of New Durable Polymer Metallic Stents
(A, B) The cobalt chromium Elixir DESyne novolimus-eluting stent crimped (A) and
(C, D) The platinum chromium everolimus-eluting Element stent crimped (C) and eingle, de novo lesions (16,17). These 2 studies are: s. The noninferiority PERSEUS Workhorse trial, which
randomized, in a 3:1 ratio, 1,262 patients with lesions
less than 28 mm long, in vessels between 2.75 and 4.00
mm in diameter, to treatment with the TAXUS Element
(n  942) or the TAXUS Express PES (n  320) (16).
At 9-month angiographic follow-up, there was no sig-
nificant difference in late loss between the Element and
Express stents (Element 0.34  0.55 mm vs. Express
0.26 0.52 mm, p 0.33). The rate of the primary end
point of target lesion failure at 12 months was 5.6%, and
6.1% for Element and Express stents, respectively (p 
0.78), which reached the pre-specified criteria for non-
inferiority. In addition, there were no significant differ-
ences in the clinical end points of MACE, mortality,
MI, and ST.
. The superiority PERSEUS Small Vessel trial, which
compared the TAXUS Element stent to historical BMS
controls in patients with lesions 20 mm in length, in
vessels between 2.25 and 2.75 mm in diameter (17).
Overall, the study enrolled 224 patients treated with the
Element stent, who were compared with 125 lesion-
matched historical controls treated with a BMS from the
TAXUS IV study. Results at 9 months follow-up dem-
onstrated a significantly lower primary end point of
in-stent late loss with the Element stent compared with
the BMS stent (0.38  0.51 mm vs. 0.80  0.53 mm,
p  0.001). At 12-month follow-up, the rates of target
lesion failure and MACE were both significantly lower
with the Element stent, whereas safety end points and
ST were comparable between both stents.
Overall, these initial, promising studies of the Element
ded (B). A is reproduced with permission from Costa et al. (14).
ed (D). Images C and D are courtesy of Boston Scientific.B
D
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xpandtent demonstrate its superiority to the BMS Express stent,
a
e
t
D
A
a
u
t
r
r
s
m
w
t
m
t
d
m
a
v
b
c
m
r
w
o
s
c
b
p
c
m
m
r
r
d
r
t
g
w
d
S
s
s
g
p
c
m
4
b
n
S
i
A
i
0
r
n
a
t
o
I
a
r
t
E
m
p
c
a
1
m
l
n
S
p
V
e
E
S
p
c
t
B
2
m
0
a
N
c
m
m
n
p
u
P
o
e
C
(
(
s
S47JACC Vol. 56, No. 10 Suppl S, 2010 Garg and Serruys
August 31, 2010:S43–78 Coronary Stents: Looking Forwardnd noninferiority to the PES Express stent with respect to
fficacy, with no apparent safety concerns. Further evalua-
ion continues.
ES With Biodegradable Polymers
t present, numerous DES with biodegradable polymers
re available commercially in Europe, with several others
ndergoing concurrent clinical trials. The physical proper-
ies of these stents, together with angiographic follow-up
esults from FIM studies or randomized trials, are summa-
ized in Table 2 (26–41). Interest has focused on these
tents because initially after implantation, they theoretically
ay offer the antirestenotic benefits of a standard DES,
hereas once the polymer has biodegraded, they specula-
ively may offer the safety benefits of a BMS.
There are many challenges remaining for this new poly-
er technology, which include, among others, establishing
he optimal biocompatibility, composition, formulation, and
egradation time of the polymer. In addition, attention
ust be paid to the pharmacokinetics of the antiproliferative
gent released by the degradation of the polymer, and the
ariation in polymer degradation time, which can be affected
y production factors such as the use of long polymer
hains, decreased polymer hydrophobicity, and greater poly-
er crystalinity, together with physical and biological envi-
onmental factors (42).
The most important remaining question, however, is
hether this new technology will lead to improved clinical
utcomes. It must be stressed that the clinical advantage of
tents with biodegradable polymers is currently hypotheti-
al. Unfortunately, present studies of these stents are limited
y short-term follow-up, and although results have been
romising, definitive data on the long-term benefits are
urrently lacking. Importantly, evidence indicates that poly-
er breakdown can be associated with a significant inflam-
atory reaction, which at times can create an acidic envi-
onment. Moreover, complications may also occur as a
esult of a persistent immune response to monomer break-
own products (43). These sequelae of polymer breakdown
eiterate the need for large-scale clinical trials with long-
erm follow-up to determine whether stents with biode-
radable polymers are as safe as, let alone safer than, stents
ith durable polymers.
Despite the aforementioned uncertainties, numerous bio-
egradable polymer stents have been developed.
irolimus based. SUPRALIMUS STENT. The Supralimus
tent (Sahajanand Medical Technologies, Gujrat, India) is a
tainless steel sirolimus-eluting stent (SES) with a biode-
radable polymer mix of poly-L-lactide (PLA), poly vinyl
yrrolidone, poly lactide-co-caprolactone, and poly lactide-
o-glycolide (PLGA). Approximately one-half of the siroli-
us has eluted by day 9, with elution being complete within
8 days; the polymer, on the other hand, completely
iodegrades within 7 months. The stents’ clinical effective-
ess and safety was initially demonstrated in the 100-patient tERIES I (Study of the Supralimus Sirolimus Eluting Stent
n the Treatment of Patients With Real World Coronary
rtery Lesions) FIM study, which reported a rate of
n-stent angiographic restenosis of 0.0% and a late loss of
.09  0.37 mm at 6-month follow-up. At 30 months, the
ate of target vessel revascularization (TVR) was 4%, with
o reported definite ST (26). Similar clinical effectiveness
nd safety have been reported at 6-month follow-up in
he larger eSERIES multicenter registry, which included
ver 1,100 patients (44).
Recently, the Supralimus stent has been compared to the
nfinnium PES (Sahajanand Medical Technologies), which
lso has a biodegradable polymer, and a BMS in the
andomized, multicenter PAINT (Percutaneous Interven-
ion With Biodegradable-Polymer Based Paclitaxel-
luting, Sirolimus-Eluting, or Bare Stents for the Treat-
ent Of De Novo Coronary Lesions) study of 274 low-risk
atients. Results demonstrated that compared with BMS
ontrols, the 2 DES stents had significantly lower late loss
nd significantly lower rates of TVR and MACE at 9- and
2-month follow-up, respectively. In addition, the Suprali-
us SES stent was shown to have a significantly lower late
oss compared with the Infinnium PES; however, this did
ot translate into any difference in clinical outcomes (39).
Further evaluation of the stent is continuing in the ongoing
ERIES III noninferiority trial that aims to randomize 400
atients to treatment with either the Xience V EES (Abbott
ascular) stent or the Supralimus SES stent, with the primary
nd point of 9-month in-stent late loss.
XCEL STENT. The stainless steel Excel stent (JW Medical
ystems, Weihai, China) is coated with sirolimus and a
oly-L-lactic acid (PLLA) biodegradable polymer, which
ompletes degradation in 6 to 9 months. Recent data from
he CREATE (Multi-Center Registry Trial of EXCEL
iodegradable Polymer Drug-Eluting Stent) registry in over
,000 patients has reported a rate of MACE of 3.1% at 18
onths follow-up, and most encouragingly, a rate of ST of
.87%, despite 80.5% of patients discontinuing clopidogrel
t 6 months (27).
EVO STENT. The NEVO stent (Cordis) is an open-cell,
obalt chromium stent, with a PLGA biodegradable poly-
er that elutes sirolimus. Uniquely, the polymer and siroli-
us are contained within reservoirs, which eliminates the
eed for a surface polymer coating, thereby reducing tissue–
olymer contact by over 75% (Fig. 3). This principle of
sing reservoirs for drug elution in combination with a
LGA biodegradable polymer is not new, and has previ-
usly been utilized on the similarly designed paclitaxel-
luting CoStar stent (Conor MedSystems, Palo Alto,
alifornia).
The CoStar stent was initially assessed in the PISCES
Paclitaxel In-Stent Controlled Elution Study), FIM Costar I
Cobalt Chromium Stent With Antiproliferative for Resteno-
is), and EuroStar (European cobalt STent with Antiprolifera-
ive for Restenosis) studies, which not only established the
Metallic Stents With a Biodegradable Polymer That Are Either Currently Available Outside the U.S., or Undergoing Clinical EvaluationTable 2 Metallic Stents With a Biodegradable Polymer That Are Either Currently Available Outside the U.S., or Undergoing Clinical Evaluation
Stent (Manufacturer)
(Ref. #) Drug (Dosage)
Drug Release (%),
Time (days)
Stent
Platform
Strut/Max
Coating
Thickness, m
Polymer Type
(Duration of
Biodegradation,
Months)
Study
(No. of Patients)
Angiographic
Follow-Up,
Months
In-Stent
Late Loss, mm
(vs. Control)
Binary
Restenosis, %
(vs. Control) Current Status
Supralimus (Sahajanand
Medical) (26)
Sirolimus
(125 g/19 mm)
50%, 9–11 SS 80/4–5 PLLA PLGA, PLC,
PVP (7)
FIM (n  100) 6 0.09 0.0 Ongoing trials
Excel stent (JW Medical
System) (27)
Sirolimus
(195–376 g)
NA SS 119/15 PLA (6–9) Registry (n  2,077) 6–12 0.21 3.8 Ongoing trials
NEVO (Cordis) (28) Sirolimus
(166 g/17 mm)
80%, 30 CoCr 99 Reservoirs of
PLGA (3)
RCT (Nevo n 202 vs.
PES n  192)
6 0.13 vs. 0.36† 1.1 vs. 8.0* Ongoing trials
BioMatrix (Biosensors)
(29,30)
Biolimus A9
(15.6 g/mm)
45%, 30 SS 112/10‡ Abluminal PLA
(6–9)
RCT (BES n  857 vs.
SES n  850)
9 0.13 vs. 0.19 20.9 vs. 23.3†§ C.E
NOBORI (Terumo) (31) Biolimus A9
(15.6 g/mm)
45%, 30 SS 112/10‡ Abluminal PLA
(6–9)
RCT (BES n  153 vs.
PES n  90)
9 0.11 vs. 0.32* 0.7 vs. 6.2* C.E.
Axxess (Devax Inc) (32) Biolimus A9
(22 g/mm)
45%, 30 Nitinol 152/15‡ Abluminal PLA
(6–9)
Registry (n  302) 9 0.29 MB
0.29 SB
2.3 MB
4.8 SB
C.E.
XTENT (Xtent) (33,34) Biolimus A9
(15.6 g/mm)
45%, 30 CoCr NA Abluminal PLA
(6–9)
Registry (n  100) 6 0.22 7.5 C.E.
SYNERGY (Boston
Scientific) (35)
Everolimus
(LD 56 g/20 mm)
(SD 113 g/20 mm)
50%, 60 PtCr 71/3 (LD)
4 (SD)
PLGA Rollcoat
Abluminal (3)
RCT (SD vs. LD vs.
PROMUS Element
n  291)
6 NA NA Ongoing trials—
to start 2010
Combo (OrbusNeich) (37) EPC  sirolimus
(5 g/mm)
NA SS NA Abluminal NA NA NA NA FIM—started
Dec 2009
Elixir Myolimus (Elixir
Medical) (38)
Myolimus
(3 g/mm)
90%, 90 CoCr 80/3 Abluminal PLA
(6–9)
FIM (n  15) 6 0.15 0 Trials—ongoing
Infinnium (Sahajanand)
(39,40)
Paclitaxel
(122 g/19 mm)
50%, 9–11 SS 80/4–5 PLLA PLGA, PLC
PVP (7)
RCT (Infinn n  111
vs. BMS n  57)
9 0.54 vs. 0.90† 8.3 vs. 25.5* C.E.
JACTAX Liberté (Boston
Scientific) (41)
Paclitaxel
(9.2 g/16 mm)
100%, 60 SS 97/1‡ JAC polymer
Abluminal (4)
FIM (n  103) 9 0.33 5.2 Trials—ongoing
All differences are not significant unless stated. *p  0.05; †p  0.001; ‡abluminal polymer; §noninferiority.
BES  biolimus-eluting stent(s); BMS  bare-metal stent(s); CoCr  cobalt chromium; EPC  endothelial progenitor capture; JAC  Juxtaposed Abluminal Coating; LD  low dose; NA  not available; PLC  75/25 poly L-lactide-co-caprolactone; PLGA  50:50 poly
DL-lactide-co-glycolide; PLLA  poly-L-lactic acid; PtCr  platinum chromium; PVP  polyvinyl pyrrolidone; SD  standard dose; SES  sirolimus-eluting stent(s); SS  stainless steel; tbc  to be confirmed; other abbreviations as in Table 1.
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August 31, 2010:S43–78 Coronary Stents: Looking Forwardptimal release kinetics for paclitaxel (10 g/30 days; ablumi-
al direction), but also demonstrated satisfactory binary in-
tent restenosis (ISR) rates and in-stent late loss (45–47).
nfortunately, disappointing results were subsequently re-
orted in the first randomized assessment of the CoStar stent,
hich was ultimately shown not to be noninferior to PES.
pecifically, the CoStar II study enrolled 1,700 patients who
ere randomized to percutaneous coronary intervention (PCI)
ith the CoStar stent (n 989) or the TAXUS PES (Boston
cientific) (n  686) (48). (Twenty-five patients were de-
egistered prior to randomization due to a failure to confirm
ngiographic inclusion criteria at the time of the index PCI.)
t 8 months, the rate of MACE was CoStar 11.0% versus
ES 6.9% (p  0.005), which was driven by the significantly
igher rate of TVR with the CoStar stent (8.1% vs. 4.3%, p
.002). Moreover, angiographic follow-up at 9 months re-
orted respective late losses for the CoStar and PES of 0.49
m and 0.18 mm, respectively (p 0.0001). Explanations for
hese results, which are in contrast to the previous CoStar
tudies, include among others, the learning curve for new
evice implantation by the investigators; changes in the man-
facturing process during the trial that may have affected the
aclitaxel release kinetics; and the small number of patients in
he earlier studies. Of great importance and relevance to the
EVO stent is that in an attempt to maximize long-term
afety, the dose of paclitaxel, which has a narrow therapeutic
indow, on the CoStar stent may have been too small to
nhibit neointimal proliferation. Conversely, in the NEVO
tent, the sirolimus dose and release kinetics are similar to those
Reser
polym
DES                                                 
BMS            
8 DAY 30 DAY
A
B
Figure 3 The NEVO Stent Design
(A) The NEVO cobalt chromium stent, which has an open-cell design and unique re
contain a biodegradable polymer and sirolimus mix that (B) completely biodegradeound on the Cypher (Cordis) SES, thus ensuring that drug slution is complete within 90 days. In addition, the highly
emo- and biocompatible polymer is also fully bioabsorbed
ithin the same period, leaving a BMS.
The stent has so far only been evaluated in the NEVO-
ES I (NEVO RES-ELUTION) study, which was a
andomized, multicenter, noninferiority study comparing
he NEVO stent to the TAXUS Liberté PES stent in 394
atients with single de novo coronary artery lesions. At
-month angiographic follow-up, the primary end point of
n-stent late lumen loss was significantly lower in patients
reated with the NEVO stent (0.13 mm vs. 0.36 mm, p 
.0001); a superiority that was preserved irrespective of
iabetes status, lesion length, or vessel diameter (28).
linical end points at both 6 months and 12 months were
umerically lower in the NEVO-treated group, although
hese differences did not reach significance. The rate of ST
as 0.0% and 1.1% (p  0.24) in patients treated with the
EVO and PES stent, respectively.
Future trials of this promising stent technology are
lanned for 2010. In particular, the NEVO II study has
ommenced and will randomize 2,500 “all-comers” to treat-
ent with either the NEVO stent or the Xience V EES
tent, with clinical follow-up planned annually out to 5
ears. Similar long-term follow-up is also planned for 1,300
.S. patients enrolled in the nonrandomized NEVO III
tudy.
iolimus A9 based. Biolimus A9 is a highly lipophilic
irolimus analogue that has been combined with an ablu-
inal PLA biodegradable polymer on a number of different
 for 
nd drug
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Coronary Stents: Looking Forward August 31, 2010:S43–78onths, and its abluminal location ensures more targeted
issue release and reduced systemic exposure. The different
tent platforms utilizing this combination have all had
ncouraging clinical results, as described later.
IOMATRIX STENT. The Biomatrix stent (Biosensors,
orges, Switzerland) was shown to be noninferior for
ACE, a composite of cardiac death, MI, and ischemia-
riven TVR at 12-month follow-up when compared with
he Cypher SES among the 1,707 patients enrolled in the
andomized, all-comers LEADERS (Limus Eluted from A
urable versus Erodable Stent coating) trial (Biomatrix
0.6% vs. Cypher 12.0%, p 0.37) (29). More recently, the
reservation of this noninferiority has been confirmed at
-year follow-up (49). Of note, the stent’s PLA polymer is
xpected to have completely biodegraded by 9 months
Fig. 4), and therefore, even though the study is not
dequately powered to detect differences in ST events, it is
romising to observe the occurrence of fewer very late ST
vents (1 year) with the Biomatrix stent (0.2% vs. 0.5%)
49). Further promising data in support of a biodegradable
olymer were obtained in an optical coherence tomography
OCT) substudy, which demonstrated a higher rate of near
omplete (95%) strut coverage with the Biomatrix stent
0
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0 1 2 3 4 5 6 7 8 9 10
Time (months)
%
 R
ec
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er
y
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B
Figure 4 The BioMatrix Flex Stent
(A) The stainless steel BioMatrix Flex stent. (B) The elution pattern of Bioli-
mus A9 (BA9) and the corresponding biodegradation pattern of the poly-lactic
acid (PLA) polymer.ahen compared with the Cypher SES at 9-months
ollow-up (89.3% vs. 63.3%, p  0.03) (50).
OBORI STENT. The Nobori stent (Terumo, Leuven, Bel-
ium) utilizes the same PLA polymer and the same anti-
roliferative agent as the aforementioned BioMatrix Flex
tent. Physically, both stent platforms are identical, the only
ifferences being the delivery system, delivery balloon, and
he stent coating process. The BioMatrix stent is coated by
n automated autopipette proprietary technology, whereas
he Nobori stent is not coated using an automated process.
he Nobori stent has so far been compared with the Cypher
ES and TAXUS PES with promising results. In the
OBORI CORE study, the reported late loss at 9-month
ollow-up between the 99 patients randomized to treatment
ith either the Nobori stent or the Cypher SES was 0.10
m, and 0.12 mm, respectively (p  0.66) (51). Moreover,
reatment with the Nobori stent also appeared to result in a
ignificantly better recovery of endothelial function (52).
his finding has subsequently been reconfirmed by Hamilos
t al. (53) who demonstrated normal vasodilation after
mplantation of the Nobori stent, in line with other second-
eneration DES and BMS, compared with the paradoxical
asoconstriction observed following implantation of first-
eneration DES.
Following on from this, the Nobori I study randomized
43 patients to treatment with either the Nobori stent (n 
53) or the TAXUS PES stent (n  90). Results at 9
onths among the 86% of patients returning for follow-up
emonstrated noninferiority, and subsequent superiority, of
he Nobori stent with respect to late loss when compared
ith the TAXUS PES stent (0.11 mm vs. 0.32 mm,
noninferiority 0.001, psuperiority  0.001). Similarly, the rate
f Academic Research Consortium (ARC)-defined ST at
-month follow-up was also lower with the Nobori stent
0.0% vs. 2.2%) (31). Overall, the evaluation of the Nobori
tent has so far been performed in over 3,000 patients, and
ncouragingly, no episodes of very late ST have been reported.
urther assessment of the stent is underway, including ran-
omized comparisons in “real-life” populations with the
ience V EES in the COMPARE 2 (n  2,700) and
ASKET PROVE 2 (n  2,400) studies; and the Cypher
elect SES in SORT-OUT IV study (n  2,400) (54).
XXESS STENT. The structural properties of the self-
xpanding, conical-shaped nitinol Axxess (Devax, Lake
orest, California) bifurcation stent are summarized in
able 2. The stent, which is deployed by withdrawing a
overing sheath, is ideally placed at the level of the carina,
hereby allowing continued easy access to both distal
ranches, which can be provisionally treated with PCI if
equired. The stent was first assessed in the 139 patient
xxess Plus registry, which reported successful implantation
f the device in the main branch in 93.5% of cases; however,
0% and 42% of patients, respectively, required 2 or 3
dditional stents to cover the lesion. Two-thirds of the 9
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August 31, 2010:S43–78 Coronary Stents: Looking Forwardevice failures occurred due to improper positioning of the
tent, either proximal or distal to the carina. At 6-month
ollow-up, in-stent late loss was 0.09 mm, whereas ISR and
LR were 4.8% and 7.5%, respectively (55). Further eval-
ation of the device has been performed in the prospective
IVERGE (Drug Eluting Stent Intervention for Treating
ide Branches Effectively) study, which recruited 302 pa-
ients, of whom 21.7% and 64.7% required additional
tenting of 1 or both branches, respectively. At 9-month
ollow-up, the rate of MACE was 7.7%, TLR 6.4%, and ST
% (32).
TENT CUSTOM NX STENT. The XTENT Custom NX
tent (Xtent, Menlo Park, California) was a unique cus-
omizable DES that had a modular design made up of
ultiple 6-mm segments that were interdigitated, allowing
or separation at each 6-mm segment (Fig. 5). These
eatures enabled the length of the stent to be customized to
he lesion length at the treatment site. The stent was
vailable with either 6 or 10 segments, allowing the
lacement of up to 36 mm or 60 mm of stent, respec-
ively. The potential benefits of this customization were
he ability to treat long lesions without overlapping
tents, and improving stent apposition and lesion cover-
ge, while maintaining vessel conformability. The stent’s
afety and efficacy were confirmed both clinically and
ngiographically in the CUSTOM I, II, and III studies
33,34). Despite its C.E. mark, the lack of randomized data,
oupled with the firm’s financial difficulties unfortunately
ead to Xtent going into liquidation in August 2009.
yolimus. MYOLIMUS-ELUTING STENT. The myolimus-
luting Elixir stent (Elixir Medical, Sunnyvale, California)
s a thin strut cobalt chromium stent coated with a PLA
olymer without any underlying primer coating. The poly-
er facilitates elution of the new macrocylic lactone, my-
A
Interdigitation           A
6mm segment
Figure 5 The Xtent
(A) The XTENT Custom NX DES System, which is composed on 6-mm separate se
using a specialized delivery stent to enable the stent length to be customizedlimus, which is produced by replacement of the oxygen on
32 of the macrocylic ring, and has a comparable potency,
n terms of inhibition of smooth muscle cells, to sirolimus.
he FIM study enrolled 15 patients, and at 6 months
ngiographic follow-up, in-stent late lumen loss, binary
estenosis, and percentage neointimal volume obstruction
ere 0.15 mm, 0.0%, and 1.4%, respectively. Clinical events
ut to 9 months consisted of 1 MI; there was no death,
LR, or ST (38). A second, single-arm multicenter registry
hat recruited 30 patients has also been completed. Half of
he patients had angiographic follow-up at 6 months,
hereas the remaining returned at 12 months. Late lumen
oss and percentage neointimal volume obstruction were
.08 mm and 3.2%, and 0.13 mm and 5.4% at 6 and 12
onths, respectively; there was no binary restenosis. Clin-
cal events, assessed at 12 months, demonstrated no mor-
ality or ST; there were, however, 2 MIs and 2 TLRs (56).
aclitaxel. INFINNIUM STENT. The Infinnium stent (Sa-
ajanand Medical Technologies) is a stainless steel stent
oated with paclitaxel, and a heparinized polymer blend of
LA, PLGA, and polyvinyl pyrrolidine. The stent’s efficacy
nd safety were confirmed in 103 low-risk patients enrolled
n the SIMPLE II (Safety and Efficacy of the Infinnium
aclitaxel-Eluting Stent) multicenter registry (40). A more
xtensive evaluation of the stent compared with the Suprali-
us stent and a BMS control was performed in the
reviously described PAINT study (39).
ACTAX STENT. The JACTAX Liberté PES stent (Boston
cientific) is a stainless steel PES stent, which has a novel
bluminal PLA polymer, known as the Juxtaposed Ablumi-
al Coating technology (JAC). This polymer has a micro-
rop structure, such that the 16-mm JACTAX stent has
,700 microdots, each containing 3.4 ng of polymer (total
B
           Separation
s that are interdigitated, and can be separated (B) in vivo
he lesion has been crossed. Image courtesy of Xtent Inc.     B
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Coronary Stents: Looking Forward August 31, 2010:S43–78.2 g) (Fig. 6). The polymer is only applied to the outer
urface of the stent, thereby ensuring that there is minimal
olymer, with little, if any, strut-to-strut or balloon-to-strut
olymer interaction. The thickness of the polymer (1 m)
s approximately 18 times less than that found on the
AXUS Liberté stent, whereas the corresponding polymer
ass is 100 times less. Paclitaxel is combined with the
olymer in a 1:1 ratio and subsequently released in a
ontrolled manner over 90 days, whereas the polymer is fully
esorbed within 6 to 9 months. The JACTAX stent is
urrently being evaluated with a coating of either low-dose
LD) or high-dose (HD) paclitaxel; nevertheless, the high-
ose preparation still only contains 1/10 of the dose of
aclitaxel as found on the TAXUS Liberté stent. Prelimi-
ary analysis of OCT data from the OCTDESI study
uggests that the use of a lower dose of paclitaxel has no
ignificant adverse effect on the stent’s overall performance.
n the OCTDESI (Optical Coherence Tomography Drug
luting Stent Investigation) study, Guagliumi randomized
0 patients to treatment with the JACTAX LD, JACTAX
D, and TAXUS Liberté stents, and reported a compara-
ive proportion of uncovered stent struts, and neointimal
olume among all 3 stents at 6 month follow-up (57).
Individually, the high-dose stent has been assessed in the
Figure 6 The JacTAX Stent Polymer
Scanning electron microscopy showing the microdrop structure of the Juxtaposed
coating technology in use on the JACTAX Liberté stent (Boston Scientific).ACTAX (Juxtaposed Abluminal Coating TAXUS)HDFIM ttudy, which enrolled 103 patients who received a JACTAX
D stent, and angiographic results were then compared with
17 historical matched controls treated with the TAXUS
iberté stent from the ATLAS study (58). The study demon-
trated lower rates of in-stent late loss (0.33 mm vs. 0.39 mm,
 0.36) and binary restenosis (5.2% vs. 9.2%, p 0.22) with
he JACTAX HD stent compared with the TAXUS Liberté
tent at 9 months follow-up. In addition, the rate of the
rimary end point of MACE (a composite of cardiac death,
I, and ischemia-driven TVR) was 7.8%, meeting the pre-
pecified criteria for noninferiority; there were no deaths,
-wave MIs, or ST during follow-up (41). Clinical evaluation
f the JACTAX LD stent is currently being performed in the
ngoing JACTAX LD DES trial, which is randomizing 130
atients to treatment with either the JACTAXLD stent or the
AXUS Liberté stent. The primary end point of MACE at 9
onths is expected to be reported in 2010.
YNERGY STENT. The SYNERGY stent (Boston Scientific) is
urrently being investigated in the 291 patient multicenter
VOLVE trial. Two doses of everolimus (PROMUS-like,
13 g/20 mm stent; and half-PROMUS, 56 g/20 mm
tent) delivered on an Element stent using an ultrathin rollcoat
bluminal bioerodable polymer (PLGA) are being compared
nal Coating (JAC)Ablumio the PROMUS Element stent. The primary clinical end
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August 31, 2010:S43–78 Coronary Stents: Looking Forwardoint is target lesion failure at 30 days, while the primary
ngiographic end point is 6-month in-stent late loss (35).
onpolymeric DES
ne step further from DES with biodegradable polymers
re DES that are completely polymer free. The perceived
dvantages of these stents include: 1) avoiding the adverse
ffects of a polymer’s presence long term; 2) improved
ealing; 3) improvement to the integrity of the stent’s
urface, as no polymer is present that can be peeled off
59,60); and 4) offering the possibility of a shorter duration
f dual antiplatelet therapy (DAPT).
Despite the absence of a polymer, these stents are still
ble to elute antiproliferative drugs in a controlled manner.
his is achieved by either:
. Dissolving the antiproliferative agent into a nonpoly-
meric biodegradable carrier on the stent’s surface.
. Impregnating the antiproliferative agent in pure form onto
the porous surface of the stent. There were initial concerns
that a porous surface would have an adverse effect on
long-term outcomes; however, this has not been substanti-
ated by the results of specific clinical studies (61).
. Attaching the antiproliferative agent directly to the stent
surface using either covalent bonding or crystallization/
chemical precipitation.
Current clinical studies of polymer-free stents are limited,
nd at present, only the YUKON DES (Translumina,
echingen, Germany) is available commercially in Europe,
hereas several others are undergoing FIM clinical studies.
he physical properties of these stents, together with angio-
raphic follow-up results from FIM studies or randomized
rials, are summarized in Table 3 (62–65). The polymer-free
ES currently undergoing investigation include:
UKON DES. The polymer-free, stainless steel YUKON
ES (Translumina) offers the unique ability to customize the
ose of rapamycin in the catheter lab. The stent has a
icroporous surface, which functions as a drug reservoir,
emoving the requirement of a polymer (66). The stent consists
f 2 components, the pre-mounted stent in a disposable
oating cartridge, and a coating device (Fig. 7). For stent
oating, the cartridge holding the stent system is placed into a
pecific coating device, and a 1-ml drug reservoir containing
issolved rapamycin in a pre-defined volume is connected to
he cartridge. Initial studies have established that the optimal
oncentration of rapamycin to prevent restenosis and TLR is
% (67). The coating process, which takes approximately 8
in, is initialized by the advancement of the drug into a
obile, positionable ring containing 3 jet units, which allow for
niform delivery of the drug into 2-m-deep pores on the
tent’s surface. After the coating has been sprayed, the stent
urface is dried by removing the solvent with pressured air,
eaving a uniform layer and a sirolimus-coated stent that is
vailable for immediate use. Po T
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Coronary Stents: Looking Forward August 31, 2010:S43–78After complete drug release, the remaining microporous
urface appears to favor the adhesion of endothelial cells.
his was initially suggested by angiographic follow-up data,
61) and more recently confirmed by OCT, which have
emonstrated significantly greater neointimal thickening
nd stent strut coverage with the YUKON stent compared
ith SES at 3-month follow-up (68).
Clinical data comes from the randomized ISAR–TEST
Intracoronary Stenting and Angiographic Restenosis–Test
quivalence Between 2 Drug-Eluting Stents) study and a
real-world” registry, which collectively have included over
00 patients treated with this 2% rapamycin concentration.
esults indicate noninferiority of the YUKON stent when
ompared with PES at 9- to 12-month follow-up (65,69).
otably, long-term data from an angiographic observational
tudy of 1,331 patients have recently reported a significantly
ower change in late loss between 6 to 8 months and 2 years
or the YUKON stent, when compared with SES and PES
YUKON 0.01  0.42 mm, SES 0.17  0.50 mm, and
ES 0.13  0.50 mm, p  0.001) (70). This important
bservation suggests that these polymer-free stents may not
e subject to the “late-catch up” phenomena that has been
eported with permanent polymer DES, and appears to be
orse in those stents using “limus”-based antiproliferative
oatings (71–73). It is interesting to note that between the
stents eluting sirolimus, the lower absolute late loss at both
months and 2 years was seen with the conventional SES.
his is consistent with the aforementioned OCT data,
ndicating greater neointimal hyperplasia with the YUKON
tent, and is likely to be related to the rapid release of
irolimus. This, together with the late loss observed with the
UKON stent, is similar to the performance of the EN-
EAVOR ZES, which also has a rapid drug release
attern, high late loss at short-term follow-up, and has been
ess susceptible to delayed restenosis compared with other
Sterile 
air
Stent Coating Machine Sin
Connection to sten
coating machine
3
Figure 7 Schematic Diagram of the YUKON Stent Coating Mac
The stent is inserted into a sterile single-use cartridge, which is then placed in the
at the appropriate dose, is used to inject the drug, which is then sprayed uniforml
pressurized air.imus DES (7,74). Clinically, use of the YUKON stent, as hith ZES, may lead to less very late ST; however, definitive
ata are lacking.
ioFreedom. The BioFreedom stent (Biosensors) is a
16L stainless steel, polymer-free stent, coated with Bioli-
us A9 (Fig. 8A). Pre-clinical studies in the porcine model
ave reported lower injury scores; lower numbers of struts
ith fibrin, granulomas, and giant cells; significantly lower
ercentage diameter stenosis, and greater endothelialization
ith the BioFreedom stent when compared with SES at
80-day follow-up (75). In addition, pharmacokinetic studies
ave demonstrated the complete absence of Biolimus A9 in the
urrounding myocardium, neointima, and on the stent itself by
80 days. Similarly, blood concentrations of Biolimus A9 have
een reported to peak 120 min after implantation, before
apidly declining such that they are barely detectable at 90 days,
nd undetectable at 180 days (76).
The first cohort of the FIM study of the BioFreedom stent
ecruited 75 relatively low-risk patients with de novo lesions
hat were less than 14 mm in length, and in coronary vessels
hat were between 2.25 and 3.00 mm in diameter. Patients
ere randomized to treatment with either a standard-dose
ioFreedom stent (15.6 g/mm), a low-dose BioFreedom
tent (7.8 g/mm), or a TAXUS PES. At 4-month follow-up,
here were no MACE or ST events with either the standard-
ose BioFreedom stent or the TAXUS PES. TheMACE rate
or the low-dose stent was 8.0%. Angiographic follow-up at 4
onths revealed a significantly lower in-stent late loss with
oth BioFreedom stents compared with PES (BioFreedom
tandard dose vs. low dose vs. TAXUS; 0.08 mm vs. 0.12 mm
s. 0.37 mm, p  0.0001 and p  0.002, respectively). A
econd cohort of 105 patients randomized to the same 3 arms
as completed recruitment, with 12-month follow-up results
vailable in late 2010 (63).
ESTAsyn sirolimus-eluting stent. This stainless steel
tent (VESTAsyn, MIV Therapeutics, Atlanta, Georgia)
Syringe
se sterile cartridge
Stent 
delivery
system
YUKON stent
ith 
nits
coating machine. The syringe, which contains the desired antiproliferative drug
the stent using the ring of 3 spray units. Finally, the stent is dried using sterilegle u
t 
Ring w
 spray u
hine
stent
y overas a nano-thin microporous hydroxyapatite surface coating
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August 31, 2010:S43–78 Coronary Stents: Looking Forwardmpregnated with a low dose (55 g) of polymer-free
irolimus (Figs. 8B and 8C). Pre-clinical studies indicate
hat this low dose of sirolimus, which is made possible by
he hydroxyapatite platform, results in reduced signs of
elayed vascular healing, thus indicating less local toxicity
nd a faster healing response (77). The elution of sirolimus
s complete within 3 months, whereas the hydroxyapatite is
table over 4 months, and has a total lifetime of 9 to 12
onths, after which it is expected to completely dissolve.
The stent has so far been assessed in the VESTASYNC I
Hydroxyapatite Polymer-Free Sirolimus-Eluting Stent for the
reatment of Single De Novo Coronary Lesions) FIM clinical
rial in 15 patients, with encouraging results (64). Angio-
raphic follow-up at 4 and 9 months demonstrated effective
eductions in late loss and intimal hyperplasia, and no evidence
f any late-catch up using either quantitative coronary angiog-
aphy (QCA) or IVUS. At 1-year follow-up, there were no
eported clinical events (64), whereas at 3 years follow-up, 1
atient had undergone a TLR (78).
Further evaluation is planned in more complex patient
roups in the VESTAsyncII study, which will enroll 75
atients randomized 3:1 to either the VESTAsyn SES or a
ontrol BMS, with a primary end point of late loss at
months follow-up (78).
mazonia Pax. The Amazonia Pax stent (Minvasys, Ge-
evilliers, France) is the only polymer-free stent that is
ade of cobalt chromium, and elutes paclitaxel. The stent
as an open-cell design, with 73-m-thick struts, which are
Figures 8 Scanning Electron Microscopy of the Surface of the
(A) BioFreedom stent and (B and C) the VESTAsync stent. The rough surface (B)
coating of the VESTAsyn stent is smoothed over (C) following the addition of 0.6 oated with a 5-m-thick abluminal coating of polymer- tree paclitaxel at a dose of 2.5 g/mm2. The pure paclitaxel
s applied using a microdrop spray crystallization process.
his consistent coating ensures that 98% of the drug is
luted within 30 days, and ensures that by 45 days all that
emains is a bare-metal cobalt chromium stent.
Clinical evaluation is ongoing. The multicenter Pax A study
andomized 30 patients to treatment with either the Amazonia
tent or the TAXUS PES (62). At 4 months, the respective
n-stent late lumen loss and percentage neointimal volume
bstruction for the Amazonia and PES were 0.77 mm versus
.42 mm (p  0.20), and 19% versus 6% (p  0.08). There
ere no deaths or ST events; however, 2 patients treated with
ES had a TLR, whereas 1 patient in the Amazonia arm had
post-procedural MI, and another had a TLR.
The ongoing Pax B study is a prospective multicenter
egistry that will enroll 100 patients. The primary end point
s angiographic in-stent late lumen loss at 9-month follow-
p, with results anticipated in late 2010 (79).
ES With Durable Polymers Versus
iodegradable Polymer Versus Polymer Free
resently, the ISAR-TEST 3 (Intracoronary Stenting and
ngiographic Restenosis Investigators–Test Efficacy of
apamycin-Eluting Stents With Different Polymer Coat-
ng Strategies) represents the only comparison of 3 stents
ith different types of polymer and the same antiprolifera-
eedom Stent and of the VESTAsync Stent
hydroxyapatite
ating of sirolimus.BioFr
of the
m coive drug (80,81). This noninferiority study randomized 605
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Coronary Stents: Looking Forward August 31, 2010:S43–78atients to rapamycin-eluting stents with either a durable
olymer (n  202), a biodegradable polymer (n  202), or
stent that was polymer free (n  201). At 6- to 8-month
ngiographic follow-up, the biodegradable polymer stent
et its pre-specified criterion for noninferiority in terms of
n-stent late lumen loss (0.23 mm vs. durable polymer 0.17
m, pnoninferiority 0.001); whereas the polymer-free stent
ailed to achieve noninferiority (0.47 mm vs. 0.17 mm,
noninferiority  0.94) (Fig. 9). Despite these results, clinical
utcomes at 1 year demonstrated a similar safety profile for
he 3 stents; however, efficacy appeared numerically inferior
ith the polymer-free stent, and comparable between the
iodegradable and durable polymer stents. At 2 years
ollow-up, clinical outcomes remained comparable in terms
f rates of mortality, MI, and stent thrombosis. The rate of
LR was also comparable between all 3 stents; however, the
bsolute increase in TLR between 1- and 2-year follow-up
as notably higher with the biodegradable polymer and
urable polymer stents, when compared with the polymer-
ree stent (2.5% vs. 2.5% vs. 0.5%). Paired angio-
raphic follow-up was available in 69% of patients, and
emonstrated a delayed in-stent late lumen loss of 0.17,
.16, and 0.01 mm for biodegradable polymer, durable
olymer, and polymer-free stents, respectively (p  0.001).
mportantly, these results indicate that not only are biode-
radable polymer stents still susceptible to the delayed
estenosis observed previously with durable polymer stents
71–73), but they also indicate that polymer free stents are
Figure 9 Results From the ISAR–TEST-3 study
In the ISAR–TEST-3 study, patients were treated with sirolimus-eluting stents that
a biodegradable polymer, or were polymer free. TLR  target lesion revascularizatiess prone to this unwanted long-term phenomenon. This Dbservation is consistent with that previously reported by
yrne et al. (70), and warrants additional investigation.
ual Polymer-Free (PF) DES Versus Durable
olymer SES Versus Durable Polymer ZES
he failure of polymer-free stents to demonstrate non-
nferiority compared with durable polymer stents in the
SAR-TEST 3 prompted interest in dual PF DES. This
pproach, which was aimed at improving the antirest-
notic performance of polymer-free stents through the use
f a second antiproliferative agent that targeted a different
art of the cell cycle, was evaluated in the ISAR–TEST-2
Intracoronary Stenting and Angiographic Restenosis–Test
fficacy of Three Limus Eluting Stents-2) study (82,83).
his study randomized 1,007 patients to treatment with
ES (n  335), ZES (n  339), or a dual PF DES (n 
33) that eluted sirolimus and the antioxidant probucol,
hich has previously been shown to reduce neointimal
yperplasia (84). The rate of the primary end point of binary
estenosis at 6- to 8-month follow-up was dual PF DES
1.0%, ZES 19.3% (p  0.001 vs. dual PF DES), and SES
2.0% (p  0.68 vs. dual PF DES). Clinical outcomes at
-year follow-up demonstrated comparable safety in terms
f mortality, MI, and ST between the 3 stents; however,
ates of TLR were significantly lower with the dual PF DES
tent compared with ZES (dual PF DES 6.8% vs. ZES
3.6%, p  0.001), and comparable with SES (dual PF
had a durable polymer,either
on.ES 6.8% vs. SES 7.2%, p  0.83).
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August 31, 2010:S43–78 Coronary Stents: Looking ForwardAt 2-year follow-up, safety clinical outcomes remained
omparable among the 3 groups (83). Similar to the 1-year
esults, rates of TLR were significantly lower with dual PF
ES compared with ZES (p  0.006), and comparable
etween dual PF and SES. Moreover, as seen in the
SAR–TEST-3, the absolute increase in TLR between 1-
nd 2-year follow-up was notably higher with the durable
olymer SES compared with the dual PF SES (3.5% vs.
0.9%, p  0.009). Likewise, paired angiographic
ollow-up demonstrated a significantly greater increase in
n-stent binary restenosis with the durable SES compared
ith the dual PF SES (6.6% vs. 2.9%, p  0.002).
verall, this study demonstrated that dual PF DES offer a
eduction in delayed restenosis compared with first-
eneration DES, while maintaining a comparable safety
rofile. Importantly, this reduction in delayed restenosis
ith the polymer-free stent is consistent with other studies
uch as ISAR–TEST and ISAR–TEST-3 (70,80,81), sug-
esting these stents may hold promise for the future.
tents With Novel Coatings
he physical properties of these stents with novel coatings,
ogether with angiographic follow-up results from FIM
tudies or randomized trials, are summarized in Table 4
85–87).
atania stent. This cobalt chromium, modified open-cell
tent (CeloNova BioSciences, Newnan, Georgia) is unique
ecause its surface is modified by a 40-nm-thick coating of
he NanoThin Polyzene-F polymer (standard DES polymer
hicknesses are 5.3–16 m). Polyzene F is a biocompatible,
iostatic, proprietary formulation of poly[bis(trifluoroethoxy)-
hosphazene], which has anti-inflammatory, bacteria-
esistant, and pro-healing qualities. Furthermore, the coating
nsures that the stent has a very low surface thrombogenicity,
hich can potentially reduce ST. The FIM ATLANTA
Assessment of The LAtest Non-Thrombogenic Angioplasty
tent) study reported a 6-month late lumen loss of 0.6 mm,
hereas at 12-month follow-up, there were no reported deaths
r MI, and a clinically driven TLR rate of 3.6% in the 55
atients treated with the Catania stent (85). No ST was
bserved, despite DAPT being given for only 30 days. In
ddition, OCT, which was performed in 15 patients, showed
etallic Stents With Novel Coatings That Are Eitherurrently Available Outside the U.S., or Undergoing Clinical EvaluaTable 4 Metallic Stents With Novel Coatings That Are EitherCurrently Available Outside the U.S., or Undergoing Cli
Stent (Manufacturer)
(Ref. #) Coating
Stent
Platform
Strut
Thickness, m Stu
Catania stent (CeloNova
Biosciences) (85)
Polyzene F CoCr 65–74 FIM
TiNOX stent (Hexacath)
(86)
Titanium Nitride-
oxide
SS 90 RCT (vs
Genous stent
(OrbusNiech) (87)
CD34 antibody SS 100 RCT (vs
ll differences are not significant unless stated. *p  0.05; †p  0.001.
Abbreviations as in Tables 1 and 2.hat 99.5% of struts were fully covered at 6 months (88).ecent registry data have also demonstrated the absence of ST
vents at 6 months follow-up among 94 patients with acute
oronary syndrome who were treated with the Catania stent
nd received only 30 days of DAPT (89). Ongoing evaluation
s taking place in the ATLANTA-II prospective registry,
hich has enrolled 300 patients, 14% of whom presented with
T-elevation MI. At 1-year follow-up, the cumulative rate of
ACE was 8.8%, with individual rates of cardiac death, MI,
nd TLR of 2.5%, 0.7%, and 6.5%, respectively. DAPT was
gain given for only 30 days, and the rate of ST was 0.7% due
o 2 cases of subacute ST (90).
itan-2 stent. The Titan-2 stent (Hexacath, Rueil-
almaison, France) is a stainless steel stent coated in
itanium-nitride oxide (Fig. 10), which has been shown to
nhibit platelet aggregation, minimize fibrin deposition,
educe inflammation, and promote healing. The TiNOX
Randomized Comparison of a Titanium-Nitride-Oxide–
oated Stent With a Stainless Steel Stent for Coronary
evascularization) study randomized 92 patients to treat-
ent with either a BMS or a BMS coated with titanium-
itride oxide, and reported a significant reduction in late loss
0.55 vs. 0.90, p  0.03) at 6-month follow-up. Clinical
valuation demonstrated significantly reduced MACE,
hich was driven primarily by a reduction in TLR, with the
itanium-coated stent at 6-month follow-up (86), with
ore recent results indicating preservation of this out to
-year follow-up (91). Additional studies include the
Evaluation
No. of Patients
(Study/Control)
Angiographic
Follow-Up,
Months
Late Loss, mm
(vs. Control)
Binary
Restenosis,%
(vs. Control)
Current
Status
n 55 6 0.60 6.8 C.E.
) n 92 (45/47) 6 0.55 vs. 0.90* 15 vs. 33 C.E.
n 193 (98/95) 6–12 1.14 vs. 0.55† NA C.E
Figure 10 The Stainless Steel Titan-2-Stent
Image courtesy of Hexacath, France.tion
nical
dy
. BMS
. PES)
T
i
M
w
s
w
a
d
T
(
r
T
t
f
t
T
s
i
T
O
n
o
1
G
l
u
a
w
r
i
r
m
a
i
b
c
(
h
h
a
(
o
h
f
P
f
b
c
l
H
I
1
c
c
r
1
(
b
D
i
m
D
p
m
f
s
C
h
t
a
S
1
S58 Garg and Serruys JACC Vol. 56, No. 10 Suppl S, 2010
Coronary Stents: Looking Forward August 31, 2010:S43–78ITAX-AMI (A Prospective, Randomized Trial Compar-
ng TITAN-2 Stent and TAXUS-Liberte Stent in Acute
yocardial Infarction) trial, which randomized 425 patients
ith ST-elevation MI to treatment with either the Titan-2
tent or the TAXUS PES stent. At 2-year follow-up, there
ere significant reductions in MACE, cardiac death, MI,
nd ST with the use of the Titan-2 stent. In addition,
espite the absence of an antiproliferative drug, the rate of
LR was still numerically lower with the Titan-2 stent
9.3% vs. 10.4%, p  0.9) (92). Three-year outcomes from
egistry data have also demonstrated favorable results for the
itan-2 stent compared with the TAXUS PES with respect
o significantly lower MACE and the absence of ST (93).
In contrast to these encouraging results, the Titan-2 stent
ailed to demonstrate noninferiority when compared with
he ZES Endeavor stent in the randomized 300-patient
IDE (Randomized Trial Comparing Titan- vs. Endeavor-
tents) study (94). At 6-month angiographic follow-up,
n-stent late lumen loss was 0.64 mm and 0.47 mm for the
itan-2 stent and ZES, respectively (pnoninferiority  0.54).
f note, differences in late lumen loss were more pro-
ounced in patients with diabetes, small vessel disease, and
ver age 65 years. Nevertheless, clinical outcomes assessed at
year were comparable.
enous Bio-engineered R-stent. This bare-metal stain-
ess steel stent (OrbusNeich, Fort Lauderdale, Florida) is
nique in containing on its luminal surface immobile CD34
ntibodies (Fig. 11). In pre-clinical studies, these antibodies
ere able bind to endothelial progenitor cells (EPCs),
esulting in a rapidly formed, functional endothelial cover-
ng of the stent’s struts, which ultimately has the potential to
educe ST and restenosis. Unfortunately, the CD34
arkers that are used to phenotype EPCs are nonspecific,
nd are shared by other hematopoietic stem cells. Therefore,
t is possible for the EPC capture stent to sequester other
one marrow cell lines such as smooth muscle progenitor
ells, which in turn can lead to neointimal proliferation
Figure 11 The Genous Stent
(A) Schematic representation of the endothelial progenitor cell (EPC) capture tech
the anti-CD-34 antibodies on the stent’s surface, promoting endothelialization. (B)95,96). This is reflected in published clinical studies that
ave shown low rates of ST despite only 1 month of DAPT;
owever, late loss at 6-month follow-up has repeatedly been
bove 0.6 mm (97–99). Recent data from the TRIAS
TRI-stent Adjudication Study) HR study, which is the
nly randomized trial published so far, reported a late loss as
igh as 1.14  0.64 mm, and an overall higher target vessel
ailure with the Genous stent compared with the TAXUS
ES (87). Encouragingly, preliminary data at 2-year
ollow-up demonstrated a lower absolute increase in TLR
etween 1 and 2 years in those treated with EPC stent
ompared to PES (100). This may reflect regression of late
oss with the EPC stent, as was previously observed in the
EALING II (Healthy Endothelial Accelerated Lining
nhibits Neointimal Growth) study in which late loss fell by
6.9% between 6 and 18 months, and/or it may reflect late
atch-up with PES (73,98). Additional promising data
ome from the 5,000 patients enrolled in e-HEALING
egistry, which reported rates of MACE, MI, and ST at
-year follow-up of 7.7%, 1.7%, and 1.0%, respectively
101).
A new application of the EPC capture technology has
een to use it to enhance vessel healing in association with
ES technology in a Combo Stent (OrbusNeich), which
ncorporates EPC capture technology together with ablu-
inal low-dose sirolimus and a biodegradable polymer.
ata from histology and OCT at 28-day follow-up in the
orcine model indicate that this combination stent pro-
otes endothelialization while also reducing neointimal
ormation and inflammation, when compared with the
tandard SES and Genous EPC stent (102). Overall, the
ombo Stent offers the potential to improve vascular
ealing while still maintaining effective control over neoin-
imal proliferation. The REMEDEE (Randomized Evalu-
tion of an Abluminal sirolimus coated Bio-Engineered
tent) FIM study has been initiated, and aims to randomize
80 patients to treatment with either the Combo Stent or
. The CD-34 antigens on the surface of the EPCs attach to
tainless steel Genous stent. B courtesy of OrbusNeich.nology
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August 31, 2010:S43–78 Coronary Stents: Looking Forwardhe TAXUS Liberté PES, with a primary end point of late
oss at 9-month follow-up (37).
The late loss of the 3 novel coated stents described in the
revious text ranges from 0.55 to 1.14 mm. Although the
esults for the Catania and Titan-2 stents are superior to
onventional BMS, they are, none the less, inferior to the
ajority of the currently available DES. A late loss of
pproximately 0.50 to 0.60 mm has been reported as the
hreshold above which a TLR is triggered (103), and this
ay explain the superior results at short-term follow-up of
he Titan-2 stent compared with BMS, and its comparable
LR with PES (86,93). The current studies of these
novel-coated” stents are limited by their small sample size,
nd it is too early to comment as to whether the absence of
n antiproliferative coating will hamper their long-term
evelopment.
iodegradable Stents (BDS)
ully BDS offer several potential advantages over con-
entional bare or drug-coated metallic stents. These
nclude potential reductions in adverse events such as ST,
ecause drug elution and vessel scaffolding are only
rovided by the stent until the vessel has healed, and as
uch, no triggers for ST, such as nonendothelialized stent
truts, or drug polymers are present long term. The
bsence of these foreign materials may also reduce the
equirements for long-term DAPT, reducing the risk of
ssociated bleeding complications. Physiologically, the
bsence of a rigid metallic casing can facilitate the return
f vessel vasomotion, adaptive shear stress, late luminal
nlargement, and late expansive remodeling.
Additional long-term advantages of using BDS include
n improvement in future treatment options, as PCI or
urgical revascularization can be performed in areas of
revious stenting without restriction. Furthermore, BDS
an negate some of the other problems associated with use
f permanent metallic stents such as the covering of side
ranches, overhang at ostial lesions, and the “blooming
ffect” seen when using noninvasive imaging techniques
uch as computed tomography angiography or MRI (104).
inally, BDS can help eliminate the concerns that a minor-
ty of patients have at the thought of having “an implant in
heir bodies for the rest of their lives” (105).
The current BDS are composed of either a polymer or a
etal alloy. Numerous different polymers are available, each
ith a different chemical composition and subsequent bio-
bsorption time. The most frequently used polymer in the
urrent generation of BDS is PLLA, which is already used
n numerous clinical items, such as resorbable sutures,
oft-tissue implants, orthopedic implants, and dialysis me-
ia. The PLLA is metabolized via the Krebs cycle over a
eriod of approximately 12 to 18 months, into small, inert
articles of carbon dioxide and water, which are then
hagocytosed by macrophages (Fig. 12) (106). TDespite the advantages, there are 3 major hurdles to using
polymer as the backbone to a coronary stent, namely, the
ack of radio-opacity, which necessitates radio-opaque stent
arkers; the reduced radial force as compared with stainless
teel, necessitating thicker stent struts; and the reduced
bility of the stents to be deformed.
BDS were first implanted in animals as early as 1980;
owever, despite the impressive results of these early stents,
amely, minimal thrombosis, moderate intimal hyperplasia,
nd a limited inflammatory response, the technology failed
o develop (107). This was primarily due to an inability to
anufacture an ideal polymer that could limit inflammation
nd restenosis (108). As described earlier, the inherent
imitations of DES have been the major driving force
ehind the current development of BDS. At present, no
DS has either the C.E. mark or U.S. FDA approval;
owever, the numerous stents that are currently undergoing
re-clinical and clinical trials are summarized in Table 5
36,109–116), and a selection of stents are described in
etail in the following text.
LLA stents. THE IGAKI-TAMAI STENT. The bare Igaki-
Figure 12 The Metabolism of PLLA
(A) The metabolism of poly-L-lactic acid (PLLA) biodegradable stents. Hydrolysis
of PLLA results in the loss of molecular weight, and reduction in strength and
mass; ultimately the PLLA is metabolized into lactic acid, carbon dioxide (CO2)
and water (H2O). (B) Bioabsorption curves for a bioabsorbable material: molec-
ular weight is lost first, followed by strength and then mass. Therefore, the
stent loses its biomedical importance long before significant mass loss has
occurred.amai PLLA coronary stent (Kyoto Medical Planning Co.
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Coronary Stents: Looking Forward August 31, 2010:S43–78td., Kyoto, Japan) degraded over 18 to 24 months and was
he first fully BDS to undergo evaluation in humans. The
tent was mounted on a standard angioplasty balloon and,
niquely, was both thermal self-expanding and balloon
xpandable. The initial self-expansion occurred following
he use of heated contrast (up to 70°C) in the delivery
alloon, whereas the final self-expansion of the stent oc-
urred at 37°C in the 20 to 30 min after stent deployment
Fig. 13).
The FIM study of the Igaki-Tamai stent (15 patients, 19
esions, 25 stents) demonstrated no MACE or ST events
ithin 30 days, and 1 repeat PCI at 6-month follow-up.
ncouragingly, the loss index (late loss/acute gain) was 0.48,
hich was comparable to BMS, and demonstrated for the
rst time that BDS did not induce excess intimal hyperpla-
ia. Furthermore, IVUS imaging demonstrated no signifi-
ant stent recoil at day 1, and as expected from the
roperties of PLLA, continued stent expansion was ob-
erved in the first 3 months of follow-up. The mean stent
ross-sectional area increased from 7.42  1.51 mm2 at
aseline to 8.18  2.42 mm2 (p  0.086) at 3 months, and
.13  2.52 mm2 at 6 months (109).
A second larger study in 50 elective patients (63 lesions,
4 stents) reported favorable long-term clinical results at 3-
nd 10-year follow-up, which currently represents the long-
st available evaluation of a BDS. The study demonstrated
he complete absence of stent struts on IVUS at 3-years
ollow-up, together with a mean angiographic diameter
tenosis of 25%. At 10-year clinical follow-up, survival rates
ree from death, cardiac death, MACE, and TLR were
9%, 98%, 60%, and 76%, respectively (110). In total, there
ere 3 ST events: 1 subacute event occurring at day 5,
Figure 13 The Igaki-Tamai Stent With Gold Markers
A marker is shown in the insert.
Photograph courtesy of Kyoto Medical Group, Japan.possibly due to inadequate heparinization at the time of PCIA
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August 31, 2010:S43–78 Coronary Stents: Looking Forward111), and 1 subsequent late and very late ST event. The
ngiographic and IVUS appearances of the stent struts out
o 10-year follow-up are shown in Figure 14 (117).
Despite the impressive results, the failure of the stent to
rogress was primarily centered on the use of heat to induce
elf-expansion. There were concerns that this could cause
ecrosis of the arterial wall leading to excessive intimal
yperplasia (118), or increased platelet adhesion leading to
T (119). None of these concerns were substantiated in the
nitial studies; however, only low-risk patients were en-
olled. Currently, the stent is only available in Europe for
eripheral use; however, there are plans to review its use in
oronary arteries. At present, the stent has no drug coating,
nd although early studies of the stent coated in the tyrosine
inase antagonist ST 638 or paclitaxel showed promising
esults, they have been confined to non-human studies
120,121).
BBOTT VASCULAR BIORESORBABLE VASCULAR SCAFFOLD
BVS). The Abbot Vascular everolimus-eluting BVS (Abbott
Figure 14 Coronary Angiograms and IVUS Images From a Right
The right coronary artery was stented with an Igaki-Tamai stent in August 2000 and fo
using a Boston Scientific Ultracross 30 MHz IVUS catheter, and the corresponding an
together with the gold stent markers (sm), and a calcium deposit (cd) (9 o’clock, A). I
(sb). The mean luminal area and mean vessel area in the stented segment were mea
follow-up (f/u). The stent markers (sm), stent struts (ss), and a calcium deposit (cd) a
respectively. (G to I) IVUS images at 9-year follow-up. The stent markers (sm) and cal
although some highly echogenic signals may represent the remnants of some struts (
to the results at 4-month follow-up (13.7 and 26.7 mm2, respectively). Reproduced wiascular) is the only PLA BDS that is currently undergoing llinical trials. The device, which is fully absorbed over 2
ears, has a backbone of PLLA, which is subsequently
oated in a thin layer of a 1:1 mixture of an amorphous
atrix of poly-D,L-lactide (PDLLA) and 8.2 g/mm of the
ntiproliferative drug everolimus. The PDLLA enables
ontrolled release of everolimus, such that 80% has been
luded by 30 days, which is similar to that seen on the
ience V EES. Encouragingly, studies also indicated that
he BVS has comparable acute vessel recoil to the EES,
nferring similar initial radial strength (122). The natural
oss of polymer mass through bioabsorption, however,
hich approximates to 30% after 1 year and to 60% after 18
onths, ensures that this radial strength is not maintained
ong term (Fig. 15). Although the stent is radiolucent, 2
latinum markers at each end allow easy visualization on
ngiography and other imaging modalities.
The first BVS device (Revision 1.0) had a strut thickness
f 150 m and a crossing profile of 1.4 mm, and consisted
f circumferential out-of-phase zigzag hoops, with struts
nary Artery Stented With an Igaki-Tamai Stent
-up for 10 years. (A to C) Baseline intravascular ultrasound (IVUS) images taken
. The stent struts (ss), which were 0.17 mm thick at baseline, are seen in A and C,
struts located at the 2, 9, 10, and 11 o’clock positions are visible, at a side branch
to be 13.06 mm2 and 27.59 mm2, respectively. (D to F) IVUS images at 4-month
een. Mean luminal area and mean vessel area were 14.00 mm2 and 31.68 mm2,
eposit (cd) are still visible 9 years after the procedure. Struts are not visible,
1 o’clock, H). The mean luminal area, and vessel area on IVUS analysis are similar
ission from Onuma et al. (117).Coro
llowed
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Coronary Stents: Looking Forward August 31, 2010:S43–78Fig. 16A). The stent had to be kept stored below 20°C to
revent physical aging of the polymer and to ensure device
tability, which was both inconvenient and limited shelf life to
weeks.
Following encouraging pre-clinical studies (123), the safety
nd feasibility of the first-generation BVS implant was assessed
n 30 low-risk patients with de novo coronary lesions who were
nrolled in the prospective, open-label, multicenter FIM
BSORB (A Bioresorbable Everolimus-Eluting Coronary
tent System for Patients With Single De-Novo Coronary
rtery Lesion) study (112,113,124,125). The study plans to
ssess clinical outcomes on an annual basis out to 5 years,
nd so far, results are available out to 3 years follow-up.
n addition, at 6 months and 2 years, to gain a greater
nderstanding of in vivo changes to the implanted device
nd local vasculature, multimodality intravascular imaging
as performed using IVUS, intravascular ultrasound-virtual
istology (IVUS-VH), palpography, and OCT.
The study demonstrated clinical safety of the BVS as
here was only 1 ischemia-driven major adverse event
non–Q-wave MI) at 6 months, whereas no MACE events
Mass loss
Mechanical integrity
Full biodegradation
Radial strength
Everolimus
elution
1 3 2 YrsMonths6
Figure 15 The Bioabsorption and Drug
Release Pattern of the BVS Device
The early loss of radial strength has been addressed with
the new Revision 1.1 BVS stent (data on file at ABBOTT Vascular).
Figure 16 The BVS Device
(A) The first-generation BVS device, Revision 1.0. (B) The second-generation device, R
zigzag pattern connected directly or by straight bridges (A, Revision 1.0) beingere reported in the following 30 months. Of note, no ST
as been observed out to 3 years follow-up (125). Angio-
raphic follow-up at 6 months demonstrated a late loss of
.44 mm, which although comparable to values from the
arly DES studies (126), and somewhat lower than histor-
cal values for BMS (0.8 mm) (127), is still notably higher
han that observed with the Xience V EES (0.11 mm)
128). Reassuringly, there was no significant increase in
elayed late loss from 6 months to 2 years among the 19
atients who returned for angiographic follow-up
p  0.23). The 6-month late loss represented a combina-
ion of neointimal hyperplasia, which was comparable to
hat observed with the Xience V EES (127), and a reduction
n scaffold area, which occurred through a combination of
cute and chronic scaffold recoil, and nonuniform vessel
upport (Fig. 17). Chronic scaffold recoil, which occurred as
consequence of the loss of radial strength with bioresorp-
ion, represents a new phenomenon that is not observed
ith nonabsorbable metallic stents.
The results from multimodality imaging during
ollow-up helped confirm bioresorption of the implant.
irect confirmation was made by observing the absence of
tent struts using IVUS and OCT at baseline and follow-up
Fig. 18). Indirect confirmation involved documenting be-
ween baseline and follow-up: 1) the reduction in hypere-
hogenicity; 2) the significant increase in strain pattern on
alpography; 3) the change in plaque composition on
VUS-VH, and 4) the return of vasoactivity following
dministration of methyl-ergometrine maleate or acetylcho-
ine (113,129,130).
Importantly, the ABSORB study not only demonstrated
he feasibility and safety of using a biodegradable scaffold,
ut it also provided vital data that have lead to important
esign modifications to the device. This second-generation
evice, Revision 1.1, utilizes the same polymer, and has the
ame total absorption time of approximately 2 years; how-
ver, a change in the processing procedure has ensured that
t is able to provide radial support for longer. Of note, the
ew design has in-phase zigzag hoops linked by bridges,
hich allows for a more consistent drug application
n 1.1. There is a clear change in the device design with the out-of-phase
ed by the in-phase hoops linked by straight bridges (B, Revision 1.1).evisio
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August 31, 2010:S43–78 Coronary Stents: Looking ForwardFig. 16B) (113) and, as recently confirmed by OCT, more
niform strut distribution and vessel wall support (131).
tent security has been improved, reducing the likelihood of
tent dislodgement, which occurred in 2 patients in Cohort
of the ABSORB study; 1 stent was successfully retrieved,
hereas 1 was deployed in a non–target vessel. Finally, from
practical aspect, the stent can now be stored at room
emperature. The device is currently being assessed in the
ecently enrolled 101-patient Cohort B ABSORB trial.
reliminary results of the first 45 patients who returned for
ngiographic follow-up at 6 months are very encouraging,
nd suggest that the medium-term performance of the
evice has been improved following changes in the manu-
acturing process and geometry of the Revision 1.1 (114).
pecifically, at 6 months, late lumen loss was 0.19 mm,
hich was notably lower than that seen with the Revision
.0, and on a par with that commonly seen with DES.
urther to that, intravascular imaging in the form of
VUS-VH and OCT both demonstrated minimal device
hrinkage with follow-up, which previously had been im-
licated in the disappointing late loss seen in Cohort A. In
ddition, the absence of any significant change in
VUS-VH signal or strut core area on OCT during
ollow-up reaffirmed the improved mechanical integrity of
he device. Finally, clinical event rates were low, with only 1
atient experiencing an MI and 1 patient experiencing a
LR; of note, there were no ST events according to
rotocol or ARC. Longer follow-up is ongoing.
Currently recruiting is the ABSORB EXTEND multi-
enter single-arm registry, which aims to eventually recruit
,000 patients, while in the pipeline for the future is a
Late Loss = 0.87 mm Late  Loss
SPIRIT -First
ML Vision  Stent
SPIRIT
Xience 
∆ Vessel Area    = -1.9% ∆ Vessel A
∆ Stent Area      = -2.0% ∆ Stent Ar
∆ Lumen Area   = -29.4% ∆ Lumen A
NIH Area (mm2) = 1.98 NIH Area (
% VO                 = 28.1% % VO       
Figure 17 A Comparison of the Temporal Changes in Quantitat
and Intravascular Ultrasound Parameters Seen in the
A comparison of the late loss, and the changes in vessel area, stent area, lumen
(%VO) between baseline and follow-up between the bare-metal Multi-Link Vision Stivotal noninferiority trial of the BVS versus a DES. sHE REVA STENT: POLY (IODINATED DESAMINOTYROSYL-
YROSINE ETHYL ESTER) CARBONATE STENT. The REVA
tent (REVA Medical, San Diego, California) is a poly(io-
inated desaminotyrosyl-tyrosine ethyl ester) carbonate
tent that degrades into water, carbon dioxide, and ethanol,
eaving iodinated desaminotyrosyl-tyrosine, which is ab-
orbed and excreted from the body (Fig. 19). The stent,
hich is radio-opaque because of the iodination of the
esaminotyrosine ring (Fig. 20), has a resorption time of
pproximately 36 months. The first version lacked an
ntiproliferative coating and had a slide and locking design
hat provided both flexibility and strength. This design
liminated hinge points and therefore minimized polymer
train by over 75%, thereby preventing deformation and
eakening of the polymer during stent deployment. Fol-
owing stent deployment, the locking mechanism main-
ained the acute lumen gain and functioned to provide
dditional support to the stent during vessel remodeling.
ata indicate minimal acute stent recoil, and radial force
hat is comparable to a BMS (132).
Following successful preclinical trials, 27 patients with de
ovo lesions were enrolled in the RESORB (REVA Endo-
ascular Study of a Bioresorbable Coronary Stent) FIM
tudy. The study demonstrated good acute reductions in
iameter stenosis following stent deployment, together with
inimal vessel shrinkage at follow-up. However, focal
echanical failures driven by polymer embrittlement led to
higher than anticipated rate of TLR (66.7%) between 4-
nd 6-month follow-up. Interestingly, the degree of neoin-
imal hyperplasia was similar to a BMS (36).
A redesign of the stent has ensued, resulting in the
. 10 mm Late Loss = 0.44 mm
rst
tent
ABSORB
BVS Stent
  = +1.2% ∆ Vessel Area    = -0.4%
  = -0.3% ∆ Stent Area      = -11.7%
 = -7.2% ∆ Lumen Area   = -16.6%
) = 0.50 NIH Area (mm2) = 0.30
  = 8.0% % VO                 = 5.5%
oronary Angiographic
RIT First and ABSORB Studies
neointimal hyperplasia area (NIH) and percentage volume obstruction
e everolimus-eluting Xience V stent, and the biodegradable BVS device. = 0
-Fi
V S
rea  
ea    
rea  
mm2
        
ive C
SPI
area,
ent, thecond-generation ReZolve stent (REVA Medical) (Fig. 20C).
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Coronary Stents: Looking Forward August 31, 2010:S43–78his stent has a more robust polymer, a spiral slide and lock
echanism to improve clinical performance, and a coating
f sirolimus. The sirolimus elution is such that 80% is eluted
y 30 days, and 95% is eluted by 90 days. Successful
re-clinical trials have been performed, and clinical trials are
nticipated to commence in late 2010 (133).
DEAL POLY(ANHYDRIDE ESTER) SALICYLIC ACID STENT.
he 8-F compatible, balloon expandable radio-opaque
DEAL BDS (Bioabsorbable Therapeutics, Menlo Park,
alifornia) is unique in that its backbone consists of
oly-anhydride ester together with salicylic acid, and an 8.3
g/mm coating of sirolimus (Fig. 21). This combination
nsures that the stent is able to provide both antiprolifera-
ive and anti-inflammatory properties. On release, salicylic
cid is absorbed into the vessel wall, and this is likely to
ccount for the reduction in inflammation seen with this
olymer, when compared with a BMS or Cypher SES
134). Sirolimus, which is present in a surface area dose that
*
#
#
#
6-months
2-years
Lumen- corrugated
Lumen - smooth
Struts absorbed
Struts absorbed
Non-apposed struts
Baseline
Figure 18 The Serial Changes Seen
on OCT in the ABSORB study
At baseline, several unapposed struts can be seen crossing the side branch
(#). At 6-month follow-up, the unapposed stent struts have been absorbed,
and the lumen has a corrugated appearance, whereas at 2-years follow-up, the
lumen is smooth, and there is little evidence to suggest that there has been a
stent implanted in this location in the past. Reprinted with permission from
Serruys et al. (113).s approximately 25% of that found on the Cypher stent, isluted over 30 days, whereas complete stent degradation
ccurs over 12 months. The stent’s radial strength at
mplant is significantly greater than both a BMS and
ypher stent; however, this decreases with bioabsorption,
uch that by approximately 60 days, it is equal to the Cypher
tent.
The 12-month follow-up of 11 patients enrolled in the
IM Whisper study was completed in July 2009. Prelimi-
ary results confirmed the stent’s safety and radial strength,
ith no evidence of acute or chronic recoil, however,
nsufficient neointimal suppression was noted (115). This is
ikely to be the consequence of the rapid elution of siroli-
us, coupled with an inadequate initial dose.
A second-generation stent has been developed with a
igher dose of sirolimus and a slower drug release pattern.
urthermore, the stent design has been optimized, which has
esulted in a reduced crossing profile (6.0-F compatible), and
hinner struts (175m). Pre-clinical porcine coronary implants
nd a FIM study are anticipated in 2010 (115).
THER PLLA BDS. Arterial Remodeling Technologies
A.R.T) (Noisy le Roi, France), Tissue Gen (Dallas, Texas),
lixir Medical, and OrbusNeich are all developing PLLA
DS; however, these stents have yet to progress beyond
re-clinical trials to date (135–137).
iodegradable metallic stent technology. ABSORBABLE
ETALLIC STENT. The balloon-expandable AMS-1 BDS
AMS-1, Biotronik, Berlin, Germany) is composed of 93%
agnesium (approximate weight of 3.0  10 mm is 3 mg)
nd 7% rare earth metals (Fig. 22). The stent has a high
echanical strength; and has notable other properties that
re comparable to stainless steel stents, such as low elastic
Figure 19 The Metabolism of Tyrosine-Polycarbonate Stents
Initially, hydrolysis of the tyrosine-polycarbonate produces iodinated
desaminotyrosyl-tyrosine ethyl esters (I2DTE), and releases carbon dioxide.
I2DTE is hydrolyzed into iodinated desaminotyrosyl-tyrosine (I2DT) and ethanol.
Cleavage of I2DT produces tyrosine and iodinated desaminotyrosine (I2DAT),
which enters the Krebs cycle.
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August 31, 2010:S43–78 Coronary Stents: Looking Forwardecoil (8%), a high collapse pressure (0.8 bar), and
inimal shortening after inflation (5%) (116). Pre-clinical
ssessment indicates the AMS-1 is rapidly endothelialized,
ith magnesium degrading within 60 days into inorganic
alts with little associated inflammatory response (138).
urthermore, the negative charge that the degradation
roduces ensures that the stent is hypothrombogenic (139).
The PROGRESS AMS (Clinical Performance and An-
iographic Results in Absorbable Metal Stents) study was a
ulticenter, nonrandomized, prospective study assessing
he efficacy and safety of the AMS-1 stent in 63 patients (71
tents) with single de novo lesions. At 12-month follow-up,
here were no deaths, MIs, or ST, thus confirming the
tent’s safety; in addition, there was also return of vessel
asoreactivity. The rate of MACE (a composite of cardiac
eath, nonfatal MI, and clinically driven TLR) was 23.8%
nd 26.7% at 4 and 12 months follow-up, respectively, and
herefore, the study achieved its primary end point; how-
ver, the rate of TLR (clinically and nonclinically driven)
as a disappointing 39.7% at 4-month and 45.0% at
2-month follow-up (116). Additional data from both
VUS and QCA indicate that the in-stent late loss of 1.08
m at 4 months was the result of the stent having a lower
nitial radial force compared with a conventional metallic
tent, and the rapid loss of this radial force as a consequence
f early, rapid AMS-1 stent degradation. Other factors
ontributing to the luminal loss seen at follow-up were
hickening of extra stent tissue (13.5%) and neointimal
Figure 20 The REVA Stent
(A) The first-generation REVA stent with the slide and lock design. (B) A demonstr
(C) The second-generation ReZolve REVA stent with the spiral slide and lock desig
and second-generation stent (E) demonstrating a greater number of stent struts w
provided courtesy of REVA Medical Inc.ormation (41%) (140). lReassuringly, angiography and IVUS at long-term
ollow-up in 8 patients who did not experience an event at
months has shown that no evidence of either later recoil or
he late development of neointima. In fact, in some patients,
vidence was seen of neointimal regression and/or an
ncrease in vessel and lumen volume (140).
Importantly, the results from this initial study have been
tilized to improve the stent’s design. Modifications have
entered on prolonging stent degradation time and enabling
rug elution, thereby reducing restenosis that was partly due
o negative remodeling, and partly due to an excessive
ealing response. The new-generation stents consist of the
MS-2 and -3.
The AMS-2 stent use a different magnesium alloy,
esulting in the stent having a higher collapse pressure and
lso a slower degradation time. Furthermore, there has been
reduction in the strut thickness from 165 m to 120 m;
n alteration to the stent’s surface; and to improve radial
trength, a change in the cross-sectional shape of the strut,
rom a rectangle to a square. These changes have had the
esired effect in pre-clinical trials (141).
The AMS-3 stent (DREAMS  Drug Eluting AMS)
s a modification of the AMS-2 stent, and is designed
ith the aim of reducing neointimal hyperplasia by
ncorporating a bioresorbable matrix for controlled re-
ease of an antiproliferative drug. The drug and its release
inetics are under investigation; however, the stent will
e assessed in the BIOSOLVE-I FIM study planned for
f the stent’s radio-opacity due to the iodination of the tyrosine molecules.
E) X-ray appearance 1 month after deployment of the first-generation stent (D)
second-generation stent following modifications to the stent polymer. Imagesation o
n. (D,
ith theate 2010 (141).
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E stents were the first stents to be implanted in coronary
rteries (142), being quickly followed by balloon-expandable
BE) stents, such that both technologies were used with
imilar frequency in the early days of coronary stenting. SE
tents are made from nitinol, an alloy of nickel and titanium,
hich is uniquely suited for this purpose given its shape
A Salicylic acid - A
Salicylic acid - A
Salicylic acid - A
Polyla
Salicylic acid -Se
Top coat
Under coat
Drug
Core
B
Figure 21 The Poly (Anhydride Ester) Salicylic Acid IDEAL Sten
(A) The stent strut in cross section indicating the location of the anti-proliferativec
Figure 22 The Absorbable Metallic Stentemory; biocompatibility; fatigue resistance; and superelas-
ic qualities that allow it to withstand large amounts of
ecoverable strain.
In addition to comparable outcomes, SE stents offer
istinct advantages over BE stents, such as a lower incidence
f edge dissections (143,144), reduced rates of side-branch
cclusion and no-reflow (144), and positive remodeling
144). Furthermore, animal data suggest that SE stents offer
he ability to prevent immediate vessel wall injury, which
ay eventually translate into a reduction in neointimal
yperplasia and a larger lumen area (145). Some of the
rawbacks associated with the use of SE stents are related
o their mechanical properties; for example, precisely
atching stent size to vessel size is hindered by the
ontinued outward radial force that SE stents exert after
eployment, leading to negative chronic recoil, and a
ubsequently larger vessel at follow-up. In addition, SE
tents are housed within a delivery catheter that ensures
tent security; however, these catheters can be cumber-
ome to use, and have an associated learning curve.
mportantly, the delivery profile of these stents is dictated
y strut dimensions, as opposed to the balloon profile in
E stents. Finally, placement accuracy of SE stents is
c acid - Salicylic acid
limus 
+ 
c acid - Salicylic acid 
c acid - Salicylic acid
e anhydride
+ 
c acid - Salicylic acid
200µm
irolimus, and the 2 salicylate polymers. (B) The gross appearance of the stent.dipi
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August 31, 2010:S43–78 Coronary Stents: Looking Forwardorward spring movements of the stent from the delivery
ystem once deployment commences.
Unfortunately, the arrival of DES led to a loss of interest
mong stent companies in pursuing the development of
E-stents, and they were largely abandoned for coronary use.
ecently, however, there appears to have been a resurgence of
nterest in this technology for niche coronary settings following
ew stent designs that have incorporated thinner struts, a drug
oating, and improved delivery systems.
At present SE stents are being investigated for use in
atients with the following.
ifurcation lesions. There is optimism that nitinol SE-
edicated bifurcation stents, which include the Axxess
Devax), Stentys (Stentys SAS, Clichy, France), and Cap-
ella Sideguard (Cappella, Auburndale, Massachusetts),
ill lead to improved outcomes in the treatment of bifur-
ation lesions, because of their ability to conform more
ptimally than a conventional BE-stent to the angulated
natomy (Table 6, Fig. 23) (32,55,146–162).
ulnerable plaque. MIs commonly result from disruption
f thin-cap fibroatheromas (163). It follows that pre-
mptive treatment of these lesions involves preventing cap
upture and promoting endothelialization. Understandably,
E-stents are not well suited to these delicate lesions owing
o the high radial forces required for their deployment.
onversely, SE stents offer the advantage of not inducing
essel injury during implantation, thereby minimizing the
isk of embolizing necrotic material and thrombus distally.
n the long term, the lack of strut penetration into necrotic
ore may reduce the risk of ST, which may occur through
he substantially delayed arterial healing that occurs when
truts penetrate the necrotic core (164,165). The vProtect
uminal Shield (Prescient Medical, Doylestown, Pennsyl-
ania) SE stent (Fig. 24A) has been shown in animal studies
o promote vascular healing, and importantly, to achieve
omplete endothelialization of the stented vessel segment
ithin 7 days (166). Furthermore, data from the FIM study
ave demonstrated that the “shield” can induce plaque
emodeling and has a positive vascular healing profile as
emonstrated on IVUS. Currently, the stent is being as-
essed in the prospective, randomized SECRITT I (San-
orini Criteria for Investigating and Treating Thin Capped
ibroatheroma Trial) pilot study, which is evaluating the
afety and feasibility of stenting a vulnerable plaque with the
Protect Luminal Shield compared with a medically treated,
onstented (control) group (167).
esions in small-diameter vessels. The use of BE stents
n vessels with small diameters is inherently associated with
risk of edge dissection, owing to the high pressures
equired for optimal stent implantation. Both inadequate
tent strut apposition and stent expansion are subsequent
isks for ST and restenosis. For lesions located in small-
ized vessels, the use of an SE stent, which can minimize
arotrauma and the risk of edge dissections, therefore offers
istinct advantages. The Cardiomind Sparrow (Cardiom-
nd, Sunnyvale, California) is a small-profile nitinol SE- ttent that is designed specifically for lesions in small-
iameter vessels (2.00 to 2.75 mm) (Figs. 24B and 24C)
168). The stent, which has a strut thickness of 61 m, is
re-loaded on an 0.014-inch guidewire, with 2 to 3 cm of
adio-opaque guidewire at the distal end enabling position-
ng within the vessel. The stent is deployed through a
edicated Sparrow delivery system that facilitates electroly-
is of mechanical latches holding down each end of the
tent. The electric current required for release of each latch
s 0.2 mA, and release occurs within 20 s. The CARE I
Cardiomind Sparrow DES Trial) feasibility study was
erformed in 21 patients with de novo lesions in vessels of
.0 to 2.5 mm diameter. At 6-month follow-up, a 13% rise
n stent volume index was observed together with a binary
estenosis rate of 20%. There was no ST at 30 days, and 2
ACE events through to 24-months follow-up (169).
The next-generation Sparrow stent has a strut thickness
f 67 m, and is coated in a 4-m-thick layer of sirolimus
t a dose of 6 g/mm, and an 8-m-thick biodegradable
LA/PLGA polymer. It is currently being assessed in the
ARE-II study that will randomize 220 patients with
esions 20 mm in length, in vessels between 2.00 and 2.75
m in diameter to treatment with the bare-metal Cardio-
ind Sparrow, the drug-coated Cardiomind Sparrow, or a
MS. Interim results at 8-months follow-up are expected in
010 (170).
edicated Bifurcation Stents
ifurcation lesions continue to pose a challenge to today’s
nterventional cardiologist. In spite of the frequent occur-
ence of bifurcation lesions, the optimal procedural strategy,
hich maintains both main- and side-branch patency,
emains to be established. Historically, a 2-stent strategy
as considered the ideal method of dealing with a bifurca-
ion lesion as this produced the best angiographic result;
owever, data from multiple randomized studies (171–176)
nd 3 recent meta-analyses indicate that a provisional
ain-branch stenting strategy is as efficacious as a 2-stent
trategy (177–179). A caveat to this, however, is the wide
natomical variation of bifurcation lesions, such that those with
large side branch supplying an extensive myocardial territory,
r a side branch with extensive disease may not be suited for a
rovisional T-stenting technique. Moreover, in those situa-
ions where a 2-stent strategy is required, debate continues over
hich stenting technique to use (176,180,181). Besides requir-
ng operator skill and experience, these conventional stenting
echniques for bifurcation lesions have a number of other
imitations, including: 1) the inability to completely scaffold the
ide-branch ostium; 2) distortion of the main-branch stent
ollowing side-branch dilation; 3) the difficulty of maintaining
ccess to the side branch throughout the procedure; 4) failure
o wire the side branch through the main-branch stent; and
Summary of the Main Characteristics and Trial Results of Currently Available Dedicated Bifurcation StentsTable 6 Summary of the Main Characteristics and Trial Results of Currently Available Dedicated Bifurcation Stents
Stent Type (Company)
(Ref. #)
Device
Profile
Stent
Material Drug Coating
SB
Protection
Ostial SB
Coverage Study Name*
No. of
Patients
(Follow-Up,
Months)
Additional
Stenting,
% MB/SB
Binary
In-Stent
Restenosis
% MB/SB
LLL, mm
MB/SB
MACE,
%
Death,
%
MI,
%
TLR,
%
Balloon-expandable stents
Antares† (TriReme Medical)
(148)
6-F SS —   FIM (TOP study) 39 (1) NA NA NA 5.9 0.0 5.1 2.9
Invatec Twin-Rail (Invatec)
(149)
6-F SS —  / FIM (DESIRE) 15 (7) 17/23 NA NA 14.3 0.0 0.0 14.3
Multi-Link Frontier†
(Abbott Vascular) (150)
7-F SS —  / Registry 105 (6) 40/43 25.3/— 0.84/0.34 17.1 0.0 3.8 13.3
Nile Croco† (Minvasys) (151) 6-F CoCr —  / Registry 93 (6) NA NA NA 12.0 2.0 0.0 9.4
Nile Pax† (Minvasys) (152) 6-F CoCr Abluminal
Paclitaxel
 / FIM 102 (30) —/27 NA NA 1.0 1.0 1.0 0.0
Petal (Boston Scientific)
(153,154)
7-F PtCr Paclitaxel   FIM (Petal Trial) 28 (12) 28/25 10/10 0.41/0.18 14.8 0.0 3.7 7.4
SideKick (Y-Med) (155) 5-F CoCr —  / FIM 17 (2–3) 40‡ NA NA 5.8 0.0 5.8 0.0
SLK-View† (Advanced Stent
Tech) (156)
8-F SS —   Registry 81 (4) 14/25 28.7/37.7 1.1/0.81 31.0 1.3 2.5 21.3
Tryton† (Tryton Medical) (157) 6-F CoCr — NA  FIM (Tryton I) 30 (6) 39/— 0/0 0.25§/0.17 9.9 3.3 6.6 6.6
Self-expanding stents
Axxess (Devax) (32,55) 7-F Nitinol Abluminal
Biolimus A9
  Registry
(DIVERGE)
302 (9) 64.7‡ 2.3/4.8 0.29/0.29 7.7 0.7 4.3 4.3
Sideguard† (Cappella)
(158,159)
6-F Nitinol — NA  FIM (Sideguard
I & II)
93 (12) NA 12/25 0.21/0.58 12.0 1.2 3.6 7.2
Stentys† (Stentys) (160,161) 7-F Nitinol Paclitaxel  / FIM (OPEN I) 40 (3¶, 6#) 9/13 25/14 0.83§ 5.1 0.0 2.5 2.5
*All multicenter studies; †C.E. mark; ‡not specified how many in main branch (MB) or side branch (SB); §proximal main branch; cardiac death; ¶clinical follow-up; #angiographic follow-up. Adapted from Abizaid et al. (162).
LLL  late lumen loss; MI  myocardial infarction; TLR  target lesion revascularization; other abbreviations as in Tables 1 and 2.
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August 31, 2010:S43–78 Coronary Stents: Looking Forward) side-branch jailing. A consequence of these limitations has
een the development of numerous dedicated bifurcation
tents, which are summarized in Table 6.
Figure 23 Self-Expanding Dedicated Bifurcation Stents
(A) Axxess, (B) Sideguard, and (C) Stentys.
Figure 24 Self-Expanding Stents
(A) The vProtect Luminal Shield stent. (B, C) The CardioMind Sparrow stent. (B) Illustrate
profile of the Sparrow stent compared with a conventional balloon-expandable stent, aThese bifurcation stents can be broadly divided into 3
roups (Figs. 23 and 25):
. Stents that facilitate provisional side-branch stenting and
maintain direct access to the side branch after main-
branch stenting. These stents consist of a pre-formed
main-branch stent with side ports to facilitate access to
the side branch. Examples include: Antares (TriReme
Medical Inc., Pleasanton, California), Invatec Twin-rail
(Invatec, Brescia, Italy), Multi-Link Frontier (Abbott
Vascular), Nile Croco (Minvasys), Petal (Boston Scien-
tific), SLK-view (Advance Stent Technologies, Pleasan-
ton, California), StenTys (StenTys), and Y-Med Side-
Kick (Y-Med, San Diego, California).
. Stents designed to treat the side branch first. These
stents are designed for those bifurcation lesions with
significant side-branch disease; a second stent is required
for the main branch. Examples include: Sideguard (Cap-
pella, Auburndale, Massachusetts), and Tryton (Tryton
Medical, Newton, Massachusetts).
. Conical stents for the geometry of the ostium. These
may require additional stents to be implanted in the main
branch or side branch. Examples include the Axxess
stent.
The newer generation of dedicated stents have significantly
mproved from the initial attempts at bifurcation stents that
ere difficult to deploy, had large crossing profiles, and had
oor trackability. The evaluation of these stents, which is
ummarized in Table 6 (32,55,148–161), is limited to small-
ized studies with short follow-up, many of which have not
een published in peer-reviewed journals.
exibility of the Sparrow stent delivery system, whereas (C) demonstrates the smaller
-F guiding catheter. (B, C) Reprinted with permission from Chamie et al. (168).s the fl
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Coronary Stents: Looking Forward August 31, 2010:S43–78Although device success has been high, studies have
eported rates of additional stenting of up to 40%. More-
ver, the early devices were bare metal, and subsequent rates
f restenosis were similar to those observed with PCI of
ifurcation lesions using BMS (182). The consequently
igh rates of MACE and TLR have prompted second-
eneration devices that elute antiproliferative drugs and
ave different stent designs, each with their own associated
earning curve. The evaluation of these newer devices is
ngoing, and although results appear more promising,
andomized trials against conventional DES are still lack-
ng. Conceptually, these dedicated stents would seem the
nswer to the problem of treating bifurcation lesions;
owever, clinical evidence is currently absent to support
heir use as first-line devices in these complex lesions.
rug-Eluting Balloons (DEBs)
EBs represent a new coronary device that may provide
healthy” future competition for DES, particularly in spe-
ific lesions where DES cannot be delivered or have
nproven results such as ISR, torturous vessels, small
essels, and long, calcified lesions.
The development of these devices, which are able to
ocally deliver antiproliferative drugs without the associated
imitations of DES, have in part been stimulated by the
reviously discussed problems of DES, such as ST and ISR.
oreover, additional impetus has been gained following the
iscovery that long-lasting antiproliferative effects do not
C
B
A
Figure 25 Balloon-Expandable Dedicated Bifurcation Stents
(A) Antares, (B) Invatec Twin-Rail, (C) Multi-Link Frontier, (D) Nile Croco/Pax, (E)equire sustained drug release. For example, the most tommonly used agent in DEB is paclitaxel, which is rapidly
aken up by vascular smooth muscle cells and retained in
hese tissues for up to 1 week, resulting in a prolonged
ntiproliferative effect (183–185).
Potential advantages of DEBs, besides their use in ISR,
nclude the absence of a polymer, which may decrease
hronic inflammation, reducing the trigger for ST. This risk
f ST may also be reduced by the absence of a rigid stent
asing, which not only removes the presence of foreign stent
truts, but also allows the original coronary anatomy to be
aintained following PCI in tortuous lesions and small
essels, thereby diminishing abnormal flow patterns. The
bsence of metal struts, and local drug delivery can also
iminish the need for prolonged DAPT.
It is important to acknowledge that DEBs cannot over-
ome some of the mechanical problems previously associ-
ted with angioplasty using noncoated balloons, such as
cute recoil. In addition, it remains unclear whether the
revious problem of late negative remodeling will occur with
EBs.
At present, several DEBs are undergoing clinical evalu-
tion, with most studies assessing their performance in the
reatment of ISR, de novo lesions, and bifurcation lesions
186–197).
All current devices use paclitaxel with a typical dose of
g/mm2 of balloon surface. The main difference between
evices is the formulation used to coat the balloon, which
ltimately facilitates drug transfer. The different formula-
(F) Tryton.F
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ogy). This proprietary drug matrix, which is applied to
the balloon of an angioplasty catheter, increases the
solubility and transfer of paclitaxel such that more than
80% of the drug is released during a single 1-min balloon
inflation, with 10% to 15% of the released paclitaxel
being delivered to the vessel wall (196). This technology
is currently used on the Paccocath (Bayer, Leverkusen,
Germany) and SeQuent Please (B. Braun, Melsungen,
Germany) DEBs. In addition, the Coroflex DEBlue
consists of a cobalt chromium BMS pre-mounted on a
SeQuent Please DEB (B. Braun).
. Paclitaxel with FreePac hydrophilic formulation. Free-
Pac is a proprietary natural coating that frees and
separates paclitaxel molecules and facilitates their ab-
sorption into the wall of the artery. It is applied to the
balloon of an angioplasty catheter, reducing total drug
elution time to 30 to 60 s. Importantly, it permits balloon
inflation to be maintained beyond 60 s without addi-
tional drug release. This technology is in use on the
IN.PACT Falcon DEB (Invatec).
. Paclitaxel without any formulation. Several different
devices elute paclitaxel without any formulation.
The DIOR DEB (Eurocor, Bonn, Germany) is loaded
ith 3 g/mm2 of paclitaxel in its microporous balloon
urface. The balloon is triple-folded, which protects the
rug from early wash-off during insertion and tracking. A
0-s balloon inflation results in the elution of a clinically
ffective dose of paclitaxel. Approximately 35% of the drug is
luted after the first 20-s inflation, with another 35% released
ollowing a second similar inflation. An extension to the
IOR balloon is the MAGICAL system, which uses a cobalt
hromium BMS on the DIOR DEB. Finally the GENIE
Acrostak, Winterthur, Switzerland) is a liquid drug delivery
atheter available in various diameters and shaft lengths. After
etermining the vessel diameter and lesion length, the balloons
re inflated with diluted paclitaxel.
DEBs have been assessed for 3 main clinical indications:
. ISR. The assessment of DEBs in patients with ISR has
shown consistent results in favor of DEBs when com-
pared with noncoated balloon angioplasty or stenting
with DES. In 2006, Scheller et al. (186) published the
results of the PACCOCATH ISR I (Paclitaxel-Coated
Balloon Catheter for In-Stent Restenosis) trial that
randomized 52 patients with angina and a single rest-
enotic coronary artery lesion to treatment with a
paclitaxel-eluting DEB or standard angioplasty balloon.
At 6-month follow-up, the primary end point of in-
segment late lumen loss was significantly lower in the
paclitaxel-eluting balloon group compared with the un-
coated balloon group (0.03  0.48 mm vs. 0.74  0.86
mm, p 0.002). Similarly, binary restenosis and MACE
were also significantly lower in the DEB group (186).
Two-year outcomes of these patients, pooled with asimilar number of patients who were of equal risk and
who were enrolled in the PACCOCATH ISR II trial,
demonstrated continued superiority of the DEB com-
pared with standard angioplasty. Specifically, treatment
with the DEB resulted in significantly lower late lumen
loss, binary restenosis, and TLR (187).
Further assessment of DEBs in the management of ISR
came in the multicenter PEPCAD II (Paclitaxel-Eluting
PTCA-Balloon Catheter in Coronary Artery Disease)
study, which randomized 131 patients to treatment with
the SeQuent Please DEB or the TAXUS PES (188). At
6-month follow-up, the primary end point of in-segment
late lumen loss was significantly lower in the DEB group
(0.17  0.42 mm vs. 0.38  0.61 mm, p  0.03),
whereas DEB-treated patients also had a trend for a
lower rate of binary restenosis (7% vs. 20%, p 0.06). At
12-month follow-up, the rate of MACE for the DEB
and PES was 9% and 22%, respectively (p  0.08),
which was largely driven by the greater need for TLR
with PES (6% vs. 15%, p  0.15). Overall, the study
demonstrated that the DEBs were well tolerated, safe,
and at least as efficacious as PES in patients with ISR.
. De novo lesions. The assessment of DEBs for de novo
lesions has been less extensive, and results are somewhat
inconsistent when compared with the superiority of
DEBs in the treatment of ISR. The SeQuent Please
DEB was assessed for the treatment of de novo lesions
with a reference vessel diameter of 2.25 to 2.8 mm in the
120-patient multicenter, prospective PEPCAD I regis-
try. Of note, approximately one-third of the patients
required additional stenting with a BMS following use of
the DEB. At 6-month follow-up, the late lumen loss in
patients treated with only a DEB was 0.18 mm, com-
pared with 0.73 mm in those receiving both DEB and
BMS. Similarly, binary restenosis rates were 5.5% and
44.8%, respectively. Although this study suggested the
safety and efficacy of the SeQuent Please, the poor
performance of the combination of DEB and BMS was
concerning and likely to be secondary to geographic
mismatch (189).
Further evaluation of the DEBs in de novo lesions came
in the noninferiority PEPCAD III study, which random-
ized 637 patients with stable/unstable angina to treatment
with a Cypher SES or the Coroflex DEBlue (BMS/
DEB combination) (B. Braun) (190). At 9-month
follow-up, the in-stent late lumen loss (0.41 mm vs. 0.16
mm, p  0.001) and ISR (10.0% vs. 2.9%, p  0.01)
were both significantly higher in the BMS/DEB arm
compared with SES. Although mortality was comparable
between groups, treatment with a BMS/DEB lead to
significantly higher rates of MI, TLR, TVR, and ST
(p  0.05 for all) at 9 months follow-up.
Some have suggested that the failure to prove noninfe-
riority in PEPCAD III was the result of using the
Cypher SES as the control arm, particularly as the late
loss in the BMS/DEB arm is somewhat comparable to
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(Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting
Stent in Small Coronary Vessel Disease) study, which
randomized 57 patients with stable or unstable angina
and small coronary vessels (2.75 mm) to PCI with the
DIOR DEB or PES, a similarly poor performance was
seen in the DEB arm (191). At 6 months follow-up,
percentage diameter stenosis (the primary end point) was
significantly worse in those treated with DEB compared
with PES (43.6  27.4% vs. 24.3  25.1%; p  0.029).
Similarly, binary restenosis and minimal lumen diameter
were also significantly worse with the DEB. Although
clinical outcomes were comparable in terms of death and
MI, there was still a trend towards higher TLR with the
DEB.
More promising data on the use of locally delivered pacli-
taxel have been reported by Herdeg et al., who randomized
204 patients to treatment with either a PES, BMS, or a
BMS followed by local delivery of fluid paclitaxel using the
GENIE device. At 6months follow-up, late lumen loss was
significantly lower in the BMS/GENIE group compared
with the BMS-only group (0.61 mm vs. 0.99 mm,
p  0.0006), and noninferior compared with PES (0.61
mm vs. 0.44 mm, pnoninferiority  0.02). Similarly, TLR
rates were 13.4%, 22.1%, and 13.4% for patients treated
with BMS/GENIE, BMS only, and PES, respectively
(192).
The evaluation of the SeQuent Please is continuing in 2
further studies of patients with de novo lesions. The
multicenter PEPCAD IV DM plans to enroll 160
diabetic patients, whereas the PEDCAD CTO will
enroll 50 patients with a chronic total occlusion (193).
. DEB for bifurcation lesions. The use of DEBs in
combination with BMS in bifurcation lesions has been
assessed in several studies, the largest of which enrolled
120 patients. In principle, the use of a DEB in the side
branch may reduce the likelihood of restenosis, thereby
reducing the requirement for side-branch stenting. Al-
though within the main branch, the use of a DEB in
combination with a BMS is needed to achieve a result
comparable with DES.
The DEBIUT (Drug Eluting Balloon in Bifurcation
Trial) registry enrolled 20 patients with bifurcation
lesions, who sequentially had the main branch and then
the side branch treated with a DIOR balloon, followed
by provisional stenting of only the main branch using a
BMS. At 4-month follow-up, there were no MACE
events; however no angiographic data were reported
(194). The second DEBIUT study was considerably
larger; randomizing 120 patients, the majority of whom
had side-branch involvement, to 1 of 3 treatment arms:
BMS  plain balloon angioplasty (POBA), BMS 
Dior DEB, or PES  POBA (197). All balloon infla-
tions prior to stenting were performed in the main
branch and side branch; all lesions were treated using the
provisional T-stent technique, and post-stenting kissing sballoon dilation was performed using a plain balloon. At
6-months angiographic follow-up, rates of main-branch
binary restenosis were lowest (not significant) in those
treated with the DEB. In the side branch, rates of binary
restenosis and late loss were also numerically lower in the
DEB arm compared with those treated with BMS 
POBA; however, both measurements were inferior to
those receiving PES. There were no overall significant
differences in clinical outcomes between all 3 arms;
notably, there were no ST events in the DEB and BMS
arms compared with a rate of 2.5% in the PES arm.
The PEPCAD V study enrolled 28 patients with bifur-
cation lesions, the majority of which were Medina class
011 or 111. Both branches were treated with the Se-
Quent Please, followed by provisional stenting of the
main branch with a BMS; 14% of side branches even-
tually received a stent. At 9-month follow-up, although
there were significant reductions in both main-branch
and side-branch late lumen loss, and only 1 TLR, of
concern were the 2 late ST events in patients receiving
DEB and BMS in the main branch (195).
Overall, DEBs have been shown to be effective in ISR;
owever, the comparison with DES in de novo lesions has
roduced inconsistent results. Currently, no DEBs have
DA approval, and many issues remain to be resolved
efore these devices can become fully accepted by regulatory
uthorities.
onclusions
he previous discussion highlights the wealth of new stent
echnology, and only time will tell which is the most
ppropriate design for the ideal coronary stent. It is clear
hat no single stent design and polymer type will be suitable
or all patients and lesion types. Therefore, a more individ-
alized choice of stent, taking into account patient charac-
eristics such as the ability to take long-term DAPT, and
esion characteristics such as presence or not of a bifurcation
esion will be important factors influencing stent selection.
eassuringly, the new stent technology appears to allow
nterventional cardiologists to make these choices, and there
s great anticipation that this will result in improved
ong-term clinical efficacy and safety.
cknowledgments
he authors would like to thank (in alphabetic order):
avide Capodanno, MD, Nils le Cerf, Keith Dawkins,
D, Refat Jabara, MD, Susanne Meis, Matthew Pollman,
D, Richard Rapoza, PhD, Steve Rowland, PhD, Profes-
or Corrado Tamburino, MD, Susan Veldhof, RN, and
rofessor Stephan Windecker, MD, who kindly reviewed
ome sections of this manuscript.
R
B
2
e
R
S73JACC Vol. 56, No. 10 Suppl S, 2010 Garg and Serruys
August 31, 2010:S43–78 Coronary Stents: Looking Forwardeprint requests and correspondence: Prof. Patrick W. Serruys,
a583a, Thoraxcenter, Erasmus Medical Center, ‘s-Gravendijkwal
30, 3015 CE Rotterdam, the Netherlands. E-mail: p.w.j.c.serruys@
rasmusmc.nl.
EFERENCES
1. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after
implantation of first-generation drug-eluting stents: a cause for
concern. Circulation 2007;115:1440–55.
2. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes
with drug-eluting stents versus bare-metal stents in Sweden. N Engl
J Med 2007;356:1009–19.
3. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized con-
trolled trials comparing drug-eluting vs. bare metal stents in coronary
artery disease: a meta-analysis. Eur Heart J 2006;27:2784–814.
4. Garg S, Serruys PW. Benefits of and safety concerns associated with
drug-eluting coronary stents. Expert Rev Cardiovasc Ther 2010;8:
449–70.
5. Garg S, Serruys PW, Onuma Y, et al. Three year clinical follow up
of the XIENCE V Everolimus eluting coronary stent system in the
treatment of patients with de novo coronary artery lesions. The
SPIRIT II Trial. J Am Coll Cardiol Intv 2009;2:1190–8.
6. Stone GW, Midei M, NewmanW, et al. Randomized comparison of
everolimus-eluting and paclitaxel-eluting stents: 2-year clinical
follow-up from the Clinical Evaluation of the Xience V Everolimus
Eluting Coronary Stent System in the Treatment of Patients with de
novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation
2009;119:680–6.
7. Hamm C. 5 years later and more than 20,000 patients studied: the
ENDEAVOR clinical program. Paper presented at: EuroPCR; May
19-22, 2009; Barcelona, Spain. Available at: http://www.pcronline.com/
Lectures/2009/5-years-later-and-more-than-20-000-patients-studied-
the-ENDEAVOR-clinical-programme. Accessed June 20, 2009.
8. Wilson GJ, Nakazawa G, Schwartz RS, et al. Comparison of
inflammatory response after implantation of sirolimus- and
paclitaxel-eluting stents in porcine coronary arteries. Circulation
2009;120:141–9, 1–2.
9. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of
delayed healing and persistent inflammation at sites of overlapping
sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270–8.
10. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug
eluting stents: importance of delayed healing. Arterioscler Thromb
Vasc Biol 2007;27:1500–10.
11. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery
between comparator polymer-based drug-eluting stents. J Am Coll
Cardiol 2008;52:333–42.
12. Niemela KO. Biodegradable coating for drug-eluting stents—more
than a facelift? Eur Heart J 2008;29:1930–1.
13. Meredith IT, Worthley S, Whitbourn R, et al. Clinical and angio-
graphic results with the next-generation Resolute stent system a
prospective, multicenter, first-in-human trial. J Am Coll Cardiol Intv
2009;2:977–85.
14. Costa JR Jr., Abizaid A, Feres F, et al. EXCELLA First-in-Man
(FIM) study: safety and efficacy of novolimus-eluting stent in de novo
coronary lesions. EuroIntervention 2008;4:53–8.
15. Abizaid A, Costa JR Jr., Feres F, et al. TCT-429: single center,
first-in-man study of the elixir novolimus eluting coronary stent
system with durable polymer 24-month clinical safety and efficacy
results (abstr). Am J Cardiol 2009;104:158D.
16. Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angio-
graphic outcomes after treatment of de novo coronary stenoses with
a novel platinum chromium thin-strut stent: primary results of the
PERSEUS (Prospective Evaluation in a Randomized Trial of the
Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-
Eluting Coronary Stent System) trial. J Am Coll Cardiol 2010;56:
264–71.
17. Kereiakes D, Cannon LA, Feldman R, et al. TAXUS PERSEUS: a
novel platinum chromium, thin-strut TAXUS Element stent for the
treatment of de novo coronary stenoses. Paper presentet at: i2summit,
American College of Cardiology; March 15, 2010; Atlanta, GA.18. Meredith IT, Worthley S, Whitbourn R, et al. The next-generation
Endeavor Resolute stent: 4-month clinical and angiographic results
from the Endeavor Resolute first-in-man trial. EuroIntervention
2007;3:50–3.
19. Udipi K, Melder RJ, Chen M, et al. The next generation Endeavor
Resolute stent: role of the BioLinx polymer system. EuroIntervention
2007;3:137–9.
20. Meredith I, Worthley S, Whitbourn R, et al. Long-term clinical
outcomes with the next generation Resolute Stent System: a report of
the 2-year follow-up from RESOLUTE clinical trial. EuroInterven-
tion 2010;5:692–97.
21. TCT-414: Three-year follow-up of a new zotarolimus-eluting stent:
results of the RESOLUTE first-in-man trial (abstr). Am J Cardiol
2009;104:153D–4D.
22. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-
eluting and everolimus-eluting coronary stents. N Engl J Med
2010;363:123–35.
23. Serruys PW, Garg S, Abizaid A, et al. A randomised comparison of
novolimus-eluting and zotarolimus-eluting stents: 9-month results of
the EXCELLA II study. EuroIntervention 2010;6:195–205.
24. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary Stenting and
Angiographic Results : Strut Thickness Effect on Restenosis Out-
come (ISAR-STEREO) Trial. Circulation 2001;103:2816–21.
25. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and
angiographic results: strut thickness effect on restenosis outcome
(ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283–8.
26. Dani S, Kukreja N, Parikh P, et al. Biodegradable-polymer-based,
sirolimus-eluting Supralimus stent: 6-month angiographic and 30-
month clinical follow-up results from the series I prospective study.
EuroIntervention 2008;4:59–63.
27. Han Y, Jing Q, Xu B, et al. Safety and efficacy of biodegradable
polymer-coated sirolimus-eluting stents in “real-world” practice:
18-month clinical and 9-month angiographic outcomes. J Am Coll
Cardiol Intv 2009;2:303–9.
28. Abizaid A. The NEVO RES Elution I study: a randomised multi-
center comparison of the NEVO reservoir-based Sirolimus eluting-
stent with the TAXUS Liberte Paclitaxel-eluting stent: first presen-
tation of the 12-month outcomes. Paper presented at: EuroPCR;
May 25–28, 2010; Paris, France. Available at: http://www.
pcronline.com/Lectures/2010/The-NEVO-RES-Elution-I-study-a-
randomised-multicentre-comparison-of-the-NEVO-reservoir-based-
Sirolimus-eluting-stent-with-the-TAXUS-Liberte-Paclitaxel-
eluting-stent-first-presentation-of-12-month-outcomes. Accessed
May 29, 2010.
29. Garg S, Sarno G, Serruys PW, et al. The twelve-month outcomes of
a biolimus eluting stent with a biodegradable polymer compared with
a sirolimus eluting stent with a durable polymer. EuroIntervention
2010;6:233–9.
30. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent
with biodegradable polymer versus sirolimus-eluting stent with du-
rable polymer for coronary revascularisation (LEADERS): a random-
ised non-inferiority trial. Lancet 2008;372:1163–73.
31. Chevalier B, Silber S, Park S-J, et al. Randomized comparison of the
Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte
paclitaxel-eluting coronary stent in patients with stenosis in native
coronary arteries: the NOBORI 1 trial—phase 2. Circ Cardiovasc
Interv 2009;2:188–95.
32. Verheye S, Agostoni P, Dubois CL, et al. 9-month clinical, angio-
graphic, and intravascular ultrasound results of a prospective evalua-
tion of the Axxess self-expanding biolimus A9-eluting stent in
coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent
Intervention for Treating Side Branches Effectively) study. J Am Coll
Cardiol 2009;53:1031–9.
33. Stella PR, Mueller R, Pavlakis G, et al. One year results of a new in
situ length-adjustable stent platform with a biodegradable biolimus
A9 eluting polymer: results of the CUSTOM-II trial. EuroInterven-
tion 2008;4:200–7.
34. Grube E. Custom clinical program. Paper presented at: EuroPCR;
May 13–16, 2008; Barcelona, Spain. Available at: http://www.
europcronline.com/fo/lecture/view_slide.php?idCongres4&id5514.
Accessed June 18, 2009.
35. Dawkins KD. The Element stent technology. Paper presented at:
EuroPCR; May 25-28, 2010; Paris, France. Available at: http://
S74 Garg and Serruys JACC Vol. 56, No. 10 Suppl S, 2010
Coronary Stents: Looking Forward August 31, 2010:S43–78www.pcronline.com/Lectures/2010/The-ELEMENT-stent-technology.
Accessed May 29, 2010.
36. Grube E. Bioabsorbable stent. The Boston Scientific and REVA
technology. Paper presented at: EuroPCR; May 19–22, 2009;
Barcelona, Spain. Available at: http://www.pcronline.com/Lectures/
2009/The-Boston-Scientific-technology. Accessed June 10, 2009.
37. Granada JF. The Orbus-Neich EPC-coated bioabsorbable polymer
sirolimus-eluting stent program. Paper presented at: Transcatheter
Cardiovascular Therapeutics; September 21, 2009; San Francisco,
CA. Available at: http://www.tctmd.com/txshow.aspx?tid939086&
id84030&trid938634. Accessed October 13, 2009.
38. Rutsch W. Multi-center first-in-man study with the lowest known
limus dose on the Elixir Medical myolimus eluting coronary stent
system with a durable polymer: nine month clinical and six month
angiographic and IVUS follow-up. Paper presented at: EuroPCR;
May 19–22, 2009; Barcelona, Spain.
39. Lemos PA, Moulin B, Perin MA, et al. Randomized evaluation of 2
drug-eluting stents with identical metallic platform and biodegrad-
able polymer but different agents (paclitaxel or sirolimus) compared
against bare stents: 1-year results of the PAINT trial. Catheter
Cardiovasc Interv 2009;74:665–73.
40. Vranckx P, Serruys PW, Gambhir S, et al. Biodegradable-polymer-
based, paclitaxel-eluting Infinnium stent: 9-Month clinical and
angiographic follow-up results from the SIMPLE II prospective
multi-centre registry study. EuroIntervention 2006;2:310–7.
41. Grube E, Schofer J, Hauptmann KE, et al. A novel paclitaxel-eluting
stent with an ultrathin abluminal biodegradable polymer 9-month
outcomes with the JACTAX HD stent. J Am Coll Cardiol Intv
2010;3:431–8.
42. Waksman R, Pakala R. Coating bioabsorption and chronic bare
metal scaffolding versus fully bioabsorbable stent. EuroIntervention
2009;5 Suppl F:F36–42.
43. De Jong WH, Eelco Bergsma J, Robinson JE, Bos RR. Tissue
response to partially in vitro predegraded poly-L-lactide implants.
Biomaterials 2005;26:1781–91.
44. Costa RA. Complex patients with coronary artery disease treated
with the novel supralimus sirolimus-eluting stents: preliminary results
of the prospective, multicentre, non-randomised E-Series trial. Paper
presented at: EuroPCR; May 19-22, 2009; Barcelona, Spain. Avail-
able at: http://www.pcronline.com/Lectures/2009/Complex-
patients-with-coronary-artery-disease-treated-with-the-novel-
supralimus-sirolimus-eluting-stents-preliminary-results-of-the-
prospective-multicentre-non-randomised-E-Series-trial. Accessed
June 10, 2009.
45. Serruys PW, Sianos G, Abizaid A, et al. The effect of variable dose
and release kinetics on neointimal hyperplasia using a novel
paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled
Elution Study (PISCES). J Am Coll Cardiol 2005;46:253–60.
46. Kaul U, Gupta RK, Mathur A, et al. Cobalt chromium stent with
antiproliferative for restenosis trial in India (COSTAR I). Indian
Heart J 2007;59:165–72.
47. Dawkins KD, Verheye S, Schuhlen H, et al. The European cobalt
STent with Antiproliferative for Restenosis trial (EuroSTAR): 12
month results. EuroIntervention 2007;3:82–8.
48. Krucoff MW, Kereiakes DJ, Petersen JL, et al. A novel bioresorbable
polymer paclitaxel-eluting stent for the treatment of single and
multivessel coronary disease: primary results of the COSTAR (Co-
balt Chromium Stent With Antiproliferative for Restenosis) II study.
J Am Coll Cardiol 2008;51:1543–52.
49. Klauss V. LEADERS: two-year follow-up from a prospective ran-
domized trial of Biolimus A9-eluting stents with a bioabsorbable
polymer vs. sirolimus-eluting stents with a durable polymer. Paper
presented at: Transcatheter Cardiovascular Therapeutics, September
22, 2009; San Francisco, CA.
50. Barlis P, Regar E, Serruys PW, et al. An optical coherence tomog-
raphy study of a biodegradable vs. durable polymer-coated limus-
eluting stent: a LEADERS trial sub-study. Eur Heart J 2010;31:
165–76.
51. Ostojic M, Sagic D, Beleslin B, et al. First clinical comparison of
Nobori Biolimus A9 eluting stents with Cypher sirolimus eluting
stents: Nobori Core nine months angiographic and one year clinical
outcomes. EuroIntervention 2008;3:574–9.52. Hamilos MI, Ostojic M, Beleslin B, et al. Differential effects of
drug-eluting stents on local endothelium-dependent coronary vaso-
motion. J Am Coll Cardiol 2008;51:2123–9.
53. Hamilos M, Sarma J, Ostojic M, et al. Interference of drug-eluting
stents with endothelium-dependent coronary vasomotion: evidence
for device-specific responses. Circ Cardiovasc Interv 2008;1:193–200.
54. Chevalier B. The NOBORI biolimus-eluting stent: comprehensive
update of the clinical trial program. Paper presented at: Transcatheter
Cardiovascular Therapeutics; September 21, 2009; San Francisco,
CA. Available at: http://www.tctmd.com/txshow.aspx?tid939082&
id84010&trid938634. Accessed November 29, 2009.
55. Grube E, Buellesfeld L, Neumann FJ, et al. Six-month clinical and
angiographic results of a dedicated drug-eluting stent for the treat-
ment of coronary bifurcation narrowings. Am J Cardiol 2007;99:
1691–7.
56. Schofer J. Multicentre, first-in-man study on the Elixir Myolimus-
eluting coronary stent system with bioabsorbable polymer: 12-month
clinical and angiographic/IVUS results. Paper presented at: EuroPCR;
May 25–28, 2010; Paris, France. Available at: http://www.
pcronline.com/Lectures/2010/Multicentre-first-in-man-study-
on-the-Elixir-Myolimus-eluting-coronary-stent-system-with-
bioabsorbable-polymer-12-month-clinical-and-angiographic-
IVUS-results. Accessed May 29, 2010.
57. Guagliumi G, Sirbu V, Musumeci G, et al. Strut coverage and vessel
wall response to a new-generation paclitaxel-eluting stent with an
ultrathin biodegradable abluminal polymer: Optical Coherence To-
mography Drug-Eluting Stent Investigation (OCTDESI). Circ Car-
diovasc Interv 2010 July 22 [E-pub ahead of print].
58. Turco MA, Ormiston JA, Popma JJ, et al. Polymer-based, paclitaxel-
eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS
ATLAS trial. J Am Coll Cardiol 2007;49:1676–83.
59. Basalus MW, Ankone MJ, van Houwelingen GK, de Man FH, von
Birgelen C. Coating irregularities of durable polymer-based drug-
eluting stents as assessed by scanning electron microscopy. EuroInt-
ervention 2009;5:157–65.
60. Otsuka Y, Chronos NA, Apkarian RP, Robinson KA. Scanning
electron microscopic analysis of defects in polymer coatings of three
commercially available stents: comparison of BiodivYsio, Taxus and
Cypher stents. J Invasive Cardiol 2007;19:71–6.
61. Dibra A, Kastrati A, Mehilli J, et al. Influence of stent surface
topography on the outcomes of patients undergoing coronary stent-
ing: a randomized double-blind controlled trial. Catheter Cardiovasc
Interv 2005;65:374–80.
62. Abizaid A. PAX A trial (Amazonia PAX versus TAXUS Liberté):
4-month follow-up: IVUS and optical coherence tomography evalu-
ation. Paper presented at: EuroPCR; May 25–28, 2010; Paris,
France. Available at: http://www.pcronline.com/Lectures/2010/
PAX-A-trial-Amazonia-PAX-versus-TAXUS-Liberte-4-month-
follow-up-IVUS-and-optical-coherence-tomography-evaluation. Ac-
cessed May 29, 2010.
63. Grube E. BioFreedom First In Man progress report. Paper presented
at: Transcatheter Cardiovascular Therapeutics; September 24, 2009;
San Francisco, CA. Available at: http://www.tctmd.com/txshow.
aspx?tid941378&id84088&trid938634. Accessed November
10, 2009.
64. Costa JR, Jr., Abizaid A, Costa R, et al. 1-Year results of the
hydroxyapatite polymer-free sirolimus-eluting stent for the treatment
of single de novo coronary lesions: the VESTASYNC I Trial. J Am
Coll Cardiol Intv 2009;2:422–7.
65. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a
nonpolymer-based rapamycin-eluting stent versus a polymer-based
paclitaxel-eluting stent for the reduction of late lumen loss. Circula-
tion 2006;113:273–9.
66. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima
formation by a novel drug-eluting stent system that allows for
dose-adjustable, multiple, and on-site stent coating. Arterioscler
Thromb Vasc Biol 2005;25:748–53.
67. Hausleiter J, Kastrati A, Wessely R, et al. Prevention of restenosis by
a novel drug-eluting stent system with a dose-adjustable, polymer-
free, on-site stent coating. Eur Heart J 2005;26:1475–81.
68. Moore P, Barlis P, Spiro J, et al. A randomized optical coherence
tomography study of coronary stent strut coverage and luminal
protrusion with rapamycin-eluting stents. J Am Coll Cardiol Intv
2009;2:437–44.
11
S75JACC Vol. 56, No. 10 Suppl S, 2010 Garg and Serruys
August 31, 2010:S43–78 Coronary Stents: Looking Forward69. Ruef J, Storger H, Schwarz F, Haase J. Comparison of a polymer-free
rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-
eluting stent (TAXUS) in real-world coronary artery lesions. Cath-
eter Cardiovasc Interv 2008;71:333–9.
70. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic
efficacy in drug-eluting stents with and without permanent polymer.
J Am Coll Cardiol Intv 2009;2:291–9.
71. Claessen BE, Beijk MA, Legrand V, et al. Two-year clinical,
angiographic, and intravascular ultrasound follow-up of the
XIENCE V Everolimus-Eluting Stent in the Treatment of Patients
With De Novo Native Coronary Artery Lesions: the SPIRIT II trial.
Circ Cardiovasc Interv 2009;2:339–47.
72. Raber L. SIRTAX-LATE: five-year clinical and angiographic
follow-up from a prospective randomized trial of sirolimus-eluting
and paclitaxel-eluting stents. Paper presented at: Transcatheter Car-
diovascular Therapeutics; September 22, 2009; San Francisco, CA.
73. Aoki J, Abizaid AC, Ong AT, Tsuchida K, Serruys PW. Serial
assessment of tissue growth inside and outside the stent after
implantation of drug-eluting stent in clinical trials. Does delayed
neointimal growth exist? EuroIntervention 2005;1:235–55.
74. Leon M. The ENDEAVOR and ENDEAVOR Resolute
zotarolimus-eluting stent: comprehensive update of the clinical trial
program (featuring the first presentation of the ENDEAVOR IV
3-year results). Paper presented at: Transcatheter Cardiovascular
Therapeutics; September 21, 2009; San Francisco, CA. Available at:
http://www.tctmd.com/txshow.aspx?tid939082&id84004&
trid938634. Accessed October 28, 2009.
75. Tada N, Virmani R, Grant G, et al. Polymer-free biolimus a9-coated
stent demonstrates more sustained intimal inhibition, improved
healing, and reduced inflammation compared with a polymer-coated
sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc
Interv 2010;3:174–83.
76. Virmani R. Are polymer-free DES safer? Observations from exper-
imental studies in animal models. Paper presented at: Transcatheter
Therapeutics; September 21, 2009; San Francisco, CA.
77. van der Giessen WJ, Sorop O, Serruys PW, Peters-Krabbendam I,
van Beusekom HMM. Lowering the dose of sirolimus, released from
a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of
delayed healing. J Am Coll Cardiol Intv 2009;2:284–90.
78. Abizaid A. The MIV VESTASYNC polymer-free sirolimus-eluting
stent program (micorporous hydroxyapatite surface). Paper presented
at: Transcatheter Cardiovascular Therapeutics; September 21, 2009;
San Francisco, CA. Available at: http://www.tctmd.com/txshow.
aspx?tid939088&id84036&trid938634. Accessed October 10,
2009.
79. Fajadet J. The Minvasys Amazonia Pax & Nile Pax polymer free
paclitaxel eluting stent programme. Paper presented at: Transcatheter
Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA.
Available at: http://www.tctmd.com/txshow.aspx?tid939088&id
84034&trid938634. Accessed October 10, 2009.
80. Mehilli J, Byrne RA, Wieczorek A, et al. Randomized trial of three
rapamycin-eluting stents with different coating strategies for the
reduction of coronary restenosis. Eur Heart J 2008;29:1975–82.
81. Byrne RA, Kufner S, Tiroch K, et al. Randomised trial of three
rapamycin-eluting stents with different coating strategies for the
reduction of coronary restenosis: 2-year follow-up results. Heart
2009;95:1489–94.
82. Byrne RA, Mehilli J, Iijima R, et al. A polymer-free dual
drug-eluting stent in patients with coronary artery disease: a
randomized trial vs. polymer-based drug-eluting stents. Eur
Heart J 2009;30:923–31.
83. Byrne RA, Kastrati A, Tiroch K, et al. 2-year clinical and angio-
graphic outcomes from a randomized trial of polymer-free dual
drug-eluting stents versus polymer-based Cypher and Endeavor,
drug-eluting stents. J Am Coll Cardiol 2010;55:2536–43.
84. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in
the prevention of restenosis after coronary angioplasty. Multivitamins
and Probucol Study Group. N Engl J Med 1997;337:365–72.
85. Tamburino C, La Manna A, Di Salvo ME, et al. First-in-man
1-year clinical outcomes of the Catania coronary stent system with
nanothin Polyzene-F in de novo native coronary artery lesions: the
ATLANTA (Assessment of The LAtest Non-Thrombogenic An-
gioplasty stent) trial. J Am Coll Cardiol Intv 2009;2:197–204.86. Windecker S, Simon R, Lins M, et al. Randomized comparison of a
titanium-nitride-oxide-coated stent with a stainless steel stent for
coronary revascularization: the TiNOX trial. Circulation 2005;111:
2617–22.
87. Beijk MA, Klomp M, Verouden N, et al. Genous endothelial
progenitor cell capturing stent versus the Taxus Liberte stent in
patients with de novo coronary lesions with a high-risk of coronary
restenosis: a randomised, single-centre, pilot study. Eur Heart J
2010;31:1055–64.
88. La Manna A, Capodanno D, Cera M, et al. Optical coherence
tomographic results at six-month follow-up evaluation of the
CATANIA coronary stent system with nanothin Polyzene-F
surface modification (from the Assessment of The LAtest Non-
Thrombogenic Angioplasty Stent [ATLANTA] trial). Am J
Cardiol 2009;103:1551–5.
89. La Manna A, Sanfilippo A, Di Salvo ME, et al. Short and mid-term
benefits of CATANIA stent in acute coronary syndromes [abstract].
Am J Cardiol 2009;104:111D.
90. La Manna A, Sanfilippo A, Di Salvo ME, et al. One-year outcomes
of CATANIA coronary stent system with nanothin polyzene-F in a
real-world unselected population: assessment of the latest non-
thrombogenic angioplasty stent 2 (Atlanta-2) study. Paper presented
at: EuroPCR; May 25-28, 2010; Paris, France.
91. Moschovitis A, Simon R, Seidenstucker A, et al. Randomised
comparison of titanium-nitride-oxide coated stents with bare metal
stents: five year follow-up of the TiNOX trial. EuroIntervention
2010;6:63–8.
92. Karjalainen PP, Ylitalo A, Niemela M, et al. Two-year follow-up
after percutaneous coronary intervention with titanium-nitride-
oxide-coated stents versus paclitaxel-eluting stents in acute myocar-
dial infarction. Ann Med 2009;41:599–607.
93. Karjalainen PP, Annala AP, Ylitalo A, Vahlberg T, Airaksinen KE.
Long-term clinical outcome with titanium-nitride-oxide-coated
stents and paclitaxel-eluting stents for coronary revascularization in
an unselected population. Int J Cardiol 2009 Apr 27 [E-pub ahead of
print].
94. Windecker S. Randomized comparison of titanium-nitride-oxide-
coated stents with zotarolimus-eluting stents for coronary revascu-
larisation. Paper presented at: EuroPCR; May 25-28, 2010, Paris,
France. Available at: http://www.pcronline.com/Lectures/2010/
Comparison-of-titanium-nitride-oxide-coated-stents-with-Zotarolimus-
eluting-stents-for-coronary-revascularisation-TIDE-a-randomised-
controlled-trial. Accessed May 29, 2010.
95. Inoue T, Sata M, Hikichi Y, et al. Mobilization of CD34-positive
bone marrow-derived cells after coronary stent implantation: impact
on restenosis. Circulation 2007;115:553–61.
96. Garg S, Duckers HJ, Serruys PW. Endothelial progenitor cell capture
stents: will this technology find its niche in contemporary practice?
Eur Heart J 2010;31:1032–5.
97. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor
cell capture by stents coated with antibody against CD34: the
HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits
Neointimal Growth-First In Man) Registry. J Am Coll Cardiol
2005;45:1574–9.
98. Duckers HJ, Silber S, de Winter R, et al. Circulating endothelial
progenitor cells predict angiographic and intravascular ultrasound
outcome following percutaneous coronary interventions in the
HEALING-II trial: evaluation of an endothelial progenitor cell
capturing stent. EuroIntervention 2007;3:67–75.
99. Duckers H, Onuma Y, Benit E, et al. Final results of the HEALING
2B Trial to evaluate a bioengineered CD34 antibody coated stent
(Genous Stent) designed to promote vascular healing by capture of
circulating endothelial progenitor cells in CAD patients. Paper
presented at: American Heart Association Scientific Sessions; No-
vember 8–12, 2008; Orlando, FL.
00. Beijk M. Two year follow-up of the endothelial progenitor cell
capturing stent versus a paclitaxel-eluting stent in patients with de
novo coronary lesions with a high-risk of coronary restenosis: the
single-centre randomised TRIAS study. Paper presented at: EuroPCR
2009; May 19-22, 2009; Barcelona, Spain.
01. Winter Rd. Can a pro-healing stent make a difference? Final
12-month outcomes from the e-HEALING 5,000 patient registry
using the EPC-coated Genous stent. Paper presented at: Transcath-
11
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
S76 Garg and Serruys JACC Vol. 56, No. 10 Suppl S, 2010
Coronary Stents: Looking Forward August 31, 2010:S43–78eter Cardiovascular Therapeutics; September 22, 2009; San Fran-
cisco, CA.
02. Granada JF, Inami S, Aboodi MS, et al. Development of a novel
prohealing stent designed to deliver sirolimus from a biodegradable
abluminal matrix. Circ Cardiovasc Interv 2010;3:257–66.
03. Ellis SG, Popma JJ, Lasala JM, et al. Relationship between angio-
graphic late loss and target lesion revascularization after coronary
stent implantation: analysis from the TAXUS-IV trial. J Am Coll
Cardiol 2005;45:1193–200.
04. Spuentrup E, Ruebben A, Mahnken A, et al. Artifact-free coronary
magnetic resonance angiography and coronary vessel wall imaging in
the presence of a new, metallic, coronary magnetic resonance imaging
stent. Circulation 2005;111:1019–26.
05. Ormiston JA, Serruys PWS. Bioabsorbable coronary stents. Circ
Cardiovasc Interv 2009;2:255–60.
06. Pietrzak WS, Sarver DR, Verstynen ML. Bioabsorbable polymer
science for the practicing surgeon. J Craniofac Surg 1997;8:87–91.
07. Waksman R. Biodegradable stents: they do their job and disappear.
J Invasive Cardiol 2006;18:70–4.
08. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked
inflammatory sequelae to implantation of biodegradable and nonbio-
degradable polymers in porcine coronary arteries. Circulation 1996;
94:1690–7.
09. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of
biodegradable poly-l-lactic acid coronary stents in humans. Circula-
tion 2000;102:399–404.
10. Nishio S, Kosuga K, Okada M, et al. Long-term (10 years) clinical
outcomes of first-in-man biodegradable poly-l-lactic acid coronary
stents. Paper presented at: EuroPCR; May 25-28, 2010; Paris,
France.
11. Tsuji T, Tamai H, Igaki K, et al. Four-year follow-up of the
biodegradable stent (IGAKI-TAMAI stent). Circ J 2004;68:135.
12. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable
everolimus-eluting coronary stent system for patients with single
de-novo coronary artery lesions (ABSORB): a prospective open-label
trial. Lancet 2008;371:899–907.
13. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable
everolimus-eluting coronary stent system (ABSORB): 2-year out-
comes and results from multiple imaging methods. Lancet 2009;373:
897–910.
14. Serruys PW. ABSORB Cohort B trial: 6-month clinical and imaging
results of the evaluation of the bioresorbable everolimus-eluting
vascular scaffold (BVS) in the treatment of patients with de novo
native coronary artery lesions. Paper presented at: EuroPCR; May
25–28, 2010; Paris, France. Available at: http://www.pcronline.com/
Lectures/2010/ABSORB-Cohort-B-trial-6-month-clinical-and-
imaging-results-of-the-evaluation-of-the-bioresorbable-Everolimus-
eluting-vascular-scaffold-BVS-in-the-treatment-of-patients-with-de-
novo-native-coronary-artery-lesions. Accessed May 29, 2010.
15. Jabara R. Poly-anhydride based on salicylic acid and adipic acid
anhydride. Paper presented at: EuroPCR; May 19–22, 2009; Barce-
lona, Spain. Available at: http://www.pcronline.com/Lectures/2009/
Poly-anhydride-based-on-salicylic-acid-and-adipic-acid-anhydride.
Accessed June 11, 2009.
16. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of
coronary arteries with bioabsorbable magnesium stents: a prospective,
non-randomised multicentre trial. Lancet 2007;369:1869–75.
17. Onuma Y, Garg S, Okamura T, et al. Ten-year follow-up of the
IGAKI-TAMAI stent. A post-humous tribute to the scientific work
of Dr. Hideo Tamai. EuroIntervention 2009;5 Suppl F:F109–11.
18. Douek PC, Correa R, Neville R, et al. Dose-dependent smooth
muscle cell proliferation induced by thermal injury with pulsed
infrared lasers. Circulation 1992;86:1249–56.
19. Post MJ, de Graaf-Bos AN, van Zanten HG, de Groot PG, Sixma
JJ, Borst C. Thrombogenicity of the human arterial wall after
interventional thermal injury. J Vasc Res 1996;33:156–63.
20. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a
specific tyrosine kinase inhibitor with biodegradable stent suppresses
the restenotic changes of the coronary artery in pigs in vivo. J Am
Coll Cardiol 1998;32:780–6.
21. Vogt F, Stein A, Rettemeier G, et al. Long-term assessment of a
novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur
Heart J 2004;25:1330–40.
122. Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo
acute stent recoil between the bioabsorbable everolimus-eluting
coronary stent and the everolimus-eluting cobalt chromium coronary
stent: insights from the ABSORB and SPIRIT trials. Catheter
Cardiovasc Interv 2007;70:515–23.
23. ABBOTT V. ABSORB trial investigator brochure. Santa Clara, CA:
ABBOTT Vascular, 2006.
24. Ormiston JA, Webster MW, Armstrong G. First-in-human implan-
tation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-
lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc
Interv 2007;69:128–31.
25. Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of
clinical follow-up after a bioresorbable everolimus-eluting scaffold in
patients with de novo coronary artery disease: the ABSORB trial.
EuroIntervention 2010 June 6 [E-pub ahead of print].
26. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-
eluting stent in patients with coronary artery disease. N Engl J Med
2004;350:221–31.
27. Serruys PW, Ong ATL, Piek JJ, et al. A randomised comparison of
a durable polymer everolimus-eluting stent with a bare metal coro-
nary stent: the SPIRIT First trial. EuroIntervention 2005;1:58–65.
28. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison
of an everolimus-eluting coronary stent with a paclitaxel-eluting
coronary stent: the SPIRIT II trial. EuroIntervention 2006;2:286–94.
29. Sarno G, Onuma Y, Garcia HM, et al. IVUS radiofrequency analysis
in the evaluation of the polymeric struts of the bioabsorbable
everolimus-eluting device during the bioabsorption process. Catheter
Cardiovasc Interv 2010;75:914–8.
30. Garcia-Garcia HM, Gonzalo N, Pawar R, et al. Assessment of the
absorption process following bioabsorbable everolimus-eluting stent
implantation: temporal changes in strain values and tissue composi-
tion using intravascular ultrasound radiofrequency data analysis. A
substudy of the ABSORB clinical trial. EuroIntervention 2009;4:
443–8.
31. Okamura T, Garg S, Gutierrez-Chico JL, et al. In-vivo evaluation of
stent strut distribution patterns in the bioabsorbable everolimus-
eluting device: an OCT ad hoc analysis of the Revision 1.0 and
Revision 1.1 stent design in the ABSORB clinical trial. EuroInter-
vention 2010;5:932–8.
32. Pollman MJ. Engineering a bioresorbable stent: REVA programme
update. EuroIntervention 2009;5 Suppl F:F54–7.
33. Abizaid A. The REVA tyrosine polycarbonate bioabsorbable stent:
lessons learned and future directions. Paper presented at: Trans-
catheter Therapeutics, September 22, 2009; San Francisco, CA.
Available at: http://www.tctmd.com/txshow.aspx?tid939090&id
84050&trid938634. Accessed October 14, 2009.
34. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-
based polymer as a drug-eluting stent coating. Catheter Cardiovasc
Interv 2008;72:186–94.
35. Lafont A, Durand E. A.R.T.: concept of a bioresorbable stent
without drug elution. EuroIntervention 2009;5 Suppl F:F83–7.
36. Yan J, Bhat V. Elixir Medical’s bioresorbable drug eluting stent
programme: an overview. EuroIntervention 2009;5 Suppl F:F80–2.
37. Cottone R, Thatcher GL, Paker S, et al. Orbus Neich fully
absorbable coronary stent platform incorporating dual partitioned
coatings. EuroIntervention 2009;5 Suppl F:F65–71.
38. Waksman R, Pakala R, Kuchulakanti PK, et al. Safety and efficacy of
bioabsorbable magnesium alloy stents in porcine coronary arteries.
Catheter Cardiovasc Interv 2006;68:607–17; discussion 618–9.
39. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich
A. Biocorrosion of magnesium alloys: a new principle in cardiovas-
cular implant technology? Heart 2003;89:651–6.
40. Waksman R, Erbel R, Di Mario C, et al. Early- and long-term
intravascular ultrasound and angiographic findings after bioabsorb-
able magnesium stent implantation in human coronary arteries. J Am
Coll Cardiol Intv 2009;2:312–20.
41. Waksman R. Current state of the absorbable metallic (magnesium)
stent. EuroIntervention 2009;5 Suppl F:F94–8.
42. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intra-
vascular stents to prevent occlusion and restenosis after transluminal
angioplasty. N Engl J Med 1987;316:701–6.43. Hirayama A, Kodama K, Adachi T, et al. Angiographic and clinical
outcome of a new self-expanding intracoronary stent (RADIUS):
11
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
S77JACC Vol. 56, No. 10 Suppl S, 2010 Garg and Serruys
August 31, 2010:S43–78 Coronary Stents: Looking Forwardresults from multicenter experience in Japan. Catheter Cardiovasc
Interv 2000;49:401–7.
44. Konig A, Schiele TM, Rieber J, Theisen K, Mudra H, Klauss V.
Stent design-related coronary artery remodeling and patterns of
neointima formation following self-expanding and balloon-
expandable stent implantation. Catheter Cardiovasc Interv 2002;56:
478–86.
45. Joner M, Nakazawa G, Bonsignore C, et al. Histopathologic evalu-
ation of nitinol self-expanding stents in an animal model of advanced
atherosclerotic lesions. EuroIntervention 2010;5:737–44.
46. Tanaka N, Martin JB, Tokunaga K, et al. Conformity of carotid
stents with vascular anatomy: evaluation in carotid models. AJNR
Am J Neuroradiol 2004;25:604–7.
47. Kaneda H, Ikeno F, Lyons J, Rezaee M, Yeung AC, Fitzgerald PJ.
Long-term histopathologic and IVUS evaluations of a novel coiled
sheet stent in porcine carotid arteries. Cardiovasc Intervent Radiol
2006;29:413–9.
48. Hermiller J. The TriReme Medical Antares sidebranch access stent:
design specifications and clinical trial results. Paper presented at
Transcatheter Cardiovascular Therapeutics; September 21, 2009;
San Francisco, CA. Available at: http://www.tctmd.com/txshow.
aspx?tid938900&id83226&trid938634. Accessed November
12, 2009.
49. Lefevre T. Invatec twin rail bifurcation stent. Paper presented at:
Transcatheter Cardiovascular Therapeutics; October 17–21, 2005;
Washington, DC. Available at: http://www.tctmd.com/Show.
aspx?id68990. Accessed November 12, 2009.
50. Lefevre T, Ormiston J, Guagliumi G, et al. The Frontier stent
registry: safety and feasibility of a novel dedicated stent for the
treatment of bifurcation coronary artery lesions. J Am Coll Cardiol
2005;46:592–8.
51. Van Geuns RJ. The Minvasys Nile paclitaxel-eluting sidebranch
access stent: results from the BiPAX study. Paper presented at:
Transcatheter Cardiovascular Therapeutics; September 21, 2009; San
Francisco, CA.
52. Costa RA. BIPAX bifurcation study: first results. Paper presented at:
EuroPCR; May 25-28, 2010; Paris, France. Available at: http://www.
pcronline.com/Lectures/2010/Bipax-bifurcation-study-first-results. Ac-
cessed May 29, 2010.
53. Ormiston J, Webster M, El-Jack S, McNab D, Plaumann SS. The
AST petal dedicated bifurcation stent: first-in-human experience.
Catheter Cardiovasc Interv 2007;70:335–40.
54. Ormiston J, Lefevre T, Grube E, Allocco D, Dawkins KD. First
Human Use of the TAXUS Petal Paclitaxel-Eluting Bifurcation
Stent. EuroIntervention 2010;6:46–53.
55. Solar RJ. The Y Med sidekick stent delivery system for the treatment
of coronary bifurcation and ostial lesions. Paper presented at: Car-
diovascular Revascularization Therapies; March 8, 2007; Washing-
ton, DC. Available at: http://www.crtonline.org/flash.aspx?
PAGE_ID4328. Accessed November 12, 2009.
56. Ikeno F, Kim YH, Luna J, et al. Acute and long-term outcomes of
the novel side access (SLK-View) stent for bifurcation coronary
lesions: a multicenter nonrandomized feasibility study. Catheter
Cardiovasc Interv 2006;67:198–206.
57. Onuma Y, Muller R, Ramcharitar S, et al. Tryton I, First-In-Man
(FIM) study: six month clinical and angiographic outcome, analysis
with new quantitative coronary angiography dedicated for bifurcation
lesions. EuroIntervention 2008;3:546–52.
58. Doi H, Maehara A, Mintz GS, Dani L, Leon MB, Grube E. Serial
intravascular ultrasound analysis of bifurcation lesions treated using
the novel self-expanding sideguard side-branch stent. Am J Cardiol
2009;104:1216–21.
59. Hauptman K. Bifurcation management using Cappella technology.
Paper presented at: EuroPCR; May 25-28, 2010; Paris, France.
Available at: http://www.pcronline.com/index.php/Lectures/2010/
Bifurcation-management-using-Cappella-technology. Accessed May
30, 2010.
60. Verheye S, Grube E, Ramcharitar S, et al. First-in-man (FIM) study
of the Stentys bifurcation stent—30 days results. EuroIntervention
2009;4:566–71.
61. Verheye S. The Stentys self-expanding stent: design specification and
clinical trial results. Paper presented at: Transcatheter Cardiovascular
Therapeutics; September 21, 2009; San Francisco, CA. Available at:http://www.tctmd.com/txshow.aspx?tid938900&id83230&
trid938634. Accessed November 14, 2009.
62. Abizaid A, de Ribamar Costa J Jr., Alfaro VJ, et al. Bifurcated stents:
giving to Caesar what is Caesar’s. EuroIntervention 2007;2:518–25.
63. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons
from sudden coronary death: a comprehensive morphological classi-
fication scheme for atherosclerotic lesions. Arterioscler Thromb Vasc
Biol 2000;20:1262–75.
64. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mecha-
nisms of fatal late coronary stent thrombosis in humans. Circulation
2003;108:1701–6.
65. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in
humans: delayed healing and late thrombotic risk. J Am Coll Cardiol
2006;48:193–202.
66. Granada JF, Pomeranz M, Heringes J, Odess I. vProtect luminal
shield system. EuroIntervention 2007;3:416–9.
67. Ramcharitar S, Gonzalo N, van Geuns RJ, et al. First case of stenting
of a vulnerable plaque in the SECRITT I trial-the dawn of a new era?
Nat Rev Cardiol 2009;6:374–8.
68. Chamie D, Costa JR Jr., Abizaid A, et al. Serial angiography and
intravascular ultrasound: results of the SISC Registry (Stents In
Small Coronaries). J Am Coll Cardiol Intv 2010;3:191–202.
69. Abizaid A. CardioMind stent. Paper presented at: Transcatheter
Cardiovascular Therapeutics; September 24, 2009; San Francisco,
CA. Available at: http://www.tctmd.com/txshow.aspx?tid939038&
id81898&trid938634. Accessed January 26, 2010.
70. Botelho R. The CARDIOMIND Sparrow DES program (CARE
II): a bioabsorbable polymer sirolimus-eluting “micro-stent.” Paper
presented at: Transcatheter Cardiovascular Therapeutics; September
21, 2009; San Francisco, CA. Available at: http://www.tctmd.com/
txshow.aspx?tid939086&&id84612&trid938634. Accessed Octo-
ber 16, 2009.
71. Latib A, Colombo A, Sangiorgi GM. Bifurcation stenting: current
strategies and new devices. Heart 2009;95:495–504.
72. Pan M, de Lezo JS, Medina A, et al. Rapamycin-eluting stents for
the treatment of bifurcated coronary lesions: a randomized com-
parison of a simple versus complex strategy. Am Heart J 2004;
148:857–64.
73. Colombo A, Moses JW, Morice MC, et al. Randomized study to
evaluate sirolimus-eluting stents implanted at coronary bifurcation
lesions. Circulation 2004;109:1244–9.
74. Jensen JS, Galløe A, Lassen JF, et al. Safety in simple versus complex
stenting of coronary artery bifurcation lesions. The nordic bifurcation
study 14-month follow-up results. EuroIntervention 2008;4:229.
75. Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of
simple versus complex drug-eluting stenting for bifurcation lesions:
the British Bifurcation Coronary Study: old, new, and evolving
strategies. Circulation 2010;121:1235–43.
76. Colombo A, Bramucci E, Sacca S, et al. Randomized study of the
crush technique versus provisional side-branch stenting in true
coronary bifurcations: the CACTUS (Coronary Bifurcations: Appli-
cation of the Crushing Technique Using Sirolimus-Eluting Stents)
study. Circulation 2009;119:71–8.
77. Brar S, Gray W, Dangas G, et al. Bifurcation stenting with
drug-eluting stents: a meta-analysis. EuroIntervention 2009;5:
475–84.
78. Zhang F, Dong L, Ge J. Simple versus complex stenting strategy for
coronary artery bifurcation lesions in the drug-eluting stent era: a
meta-analysis of randomized trials. Heart 2009;95:1676–81.
79. Katritsis DG, Siontis GCM, Ioannidis JPA. Double versus single
stenting for coronary bifurcation lesions: a meta-analysis. Circ Car-
diovasc Intervent 2009;2:409–15.
80. Erglis A, Kumsars I, Niemela M, et al. Randomized comparison of
coronary bifurcation stenting with the crush versus the culotte
technique using sirolimus eluting stents: the Nordic Stent Technique
study. Circ Cardiovasc Interv 2009;2:27–34.
81. Ge L, Iakovou I, Cosgrave J, et al. Treatment of bifurcation lesions
with two stents: one year angiographic and clinical follow up of crush
versus T stenting. Heart 2006;92:371–6.
82. Yamashita T, Nishida T, Adamian MG, et al. Bifurcation lesions:
two stents versus one stent—immediate and follow-up results. J Am
Coll Cardiol 2000;35:1145–51.
11
1
1
1
1
1
1
1
1
1
1
1
1
1
K
p
F
t
S78 Garg and Serruys JACC Vol. 56, No. 10 Suppl S, 2010
Coronary Stents: Looking Forward August 31, 2010:S43–7883. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial
smooth muscle cell proliferation and migration in vitro and in vivo
using local drug delivery. Circulation 1997;96:636–45.
84. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery
for the prevention of restenosis: biological effects and efficacy in vivo.
J Am Coll Cardiol 2000;35:1969–76.
85. Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K,
Honjo H. Retention of paclitaxel in cancer cells for 1 week in vivo
and in vitro. Cancer Chemother Pharmacol 2006;58:665–72.
86. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary
in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl
J Med 2006;355:2113–24.
87. Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after
treatment of coronary in-stent restenosis with a paclitaxel-coated
balloon catheter. Clin Res Cardiol 2008;97:773–81.
88. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated
balloon catheter versus paclitaxel-coated stent for the treatment of
coronary in-stent restenosis. Circulation 2009;119:2986–94.
89. Maier LS, Maack C, Ritter O, Bohm M. Hotline update of
clinical trials and registries presented at the German Cardiac
Society meeting 2008. (PEPCAD, LokalTax, INH, German abla-
tion registry, German device registry, DES.DE registry, DHR,
Reality, SWEETHEART registry, ADMA, GERSHWIN). Clin
Res Cardiol 2008;97:356–63.
90. Hamm C. Paclitaxel-eluting PTCA-balloon in combination with the
Coroflex Blue stent vs. the sirolimus coated Cypher stent in the
treatment of advanced coronary artery disease. Paper presented at:
American Heart Association Scientific Sessions 2009; November 14,
2009; Orlando, FL.
91. Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon
versus drug-eluting stent during PCI of small coronary vessels, a
prospective randomised clinical trial. The PICCOLETO Study.
Heart 2010;96:1291–6.
92. Herdeg C, Gohring-Frischholz K, Haase KK, et al. Catheter-based
delivery of fluid paclitaxel for prevention of restenosis in native mcoronary artery lesions after stent implantation. Circ Cardiovasc
Interv 2009;2:294–301.
93. Unverdorben M. Summarizing the B. Braun PEPCAD coronary
paclitaxel-eluting balloon clinical studies. Paper presented at: Trans-
catheter Cardiovascular Therapeutics; September 22, 2009; San
Francisco, CA. Available at: http://www.tctmd.com/txshow.aspx?
tid939092&id84062&trid938634. Accessed January 14, 2010.
94. Fanggiday JC, Stella PR, Guyomi SH, Doevendans PA. Safety
and efficacy of drug-eluting balloons in percutaneous treatment of
bifurcation lesions: the DEBIUT (drug-eluting balloon in bifur-
cation Utrecht) registry. Catheter Cardiovasc Interv 2008;71:
629–35.
95. Mathey DG. The PEPCAD V bifurcation study. Paper presented at:
Transcatheter Cardiovascular Therapeutics; September 22, 2009; San
Francisco, CA. Available at: http://www.tctmd.com/txshow.aspx?
tid939092&id84154&trid938634. Accessed January 14, 2010.
96. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig
G. Paclitaxel balloon coating, a novel method for prevention and
therapy of restenosis. Circulation 2004;110:810–4.
97. Stella P. Drug eluting balloons in coronary bifurcations: the Drug
Eluting Balloon In Bifurcation trial. Paper presented at: EuroPCR;
May 25–28, 2010; Paris, France. Available at: http://www.
pcronline.com/Lectures/2010/The-DEBIUT-trial. Accessed May
29, 2010.
ey Words: drug-eluting stents y biodegradable stents y biodegradable
olymer stents y polymer-free drug-eluting stents y coronary stents.
APPENDIX
or a list of all study acronyms and their definitions, please see Appendix I in
he online version of this article; and for a list of all study devices and their
anufacturers, please see Appendix II in the online version of this article.
